A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 3 Different Extended-release Formulations of Verinurad in Healthy Subjects
Phase: PHASE1
Conditions: Chronic Kidney Disease
Sponsor: AstraZeneca

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
1 of 94
Clinical Study Protocol
A Randomised, Single-dose, 5-period, 5-treatment, Crossover 
Study to Assess the Relative Bioavailability of 3 Different 
Extended-release Formulations of Verinurad in Healthy Subjects
PAREXEL Study No.:
Sponsor Study Code:
D5495C00005
IND No./Eudra CT No:
2019-001446-18
Study Type:
Randomised, single-dose, crossover study
Reference Product:
Verinurad (RDEA3170), ER8 capsules
12 mg: 1 x 12 mg dose
Test Product:
Verinurad (RDEA3170), A-capsule
12 mg: 2 x 6 mg dose
Verinurad (RDEA3170), B-capsule
12 mg: 2 x 6 mg dose
Therapeutic Indication:
Chronic kidney disease
Pharmacological Class:
URAT1 inhibitor
Development Phase:
Phase 1
Sponsor:
AstraZeneca AB
151 85 Södertälje
Sweden
Study Centre:
PAREXEL Early Phase Clinical Unit Berlin
On the premises of DRK Kliniken Berlin Westend, Haus 31
Spandauer Damm 130
14050 Berlin
Germany
Date of Protocol:
Final 1.0, 06 May 2019
Date of Protocol Amendment #1
Final 1.0, 24 June 2019
This clinical study will be conducted according to the protocol and in compliance with Good 
Clinical Practice, with the Declaration of Helsinki (Version 1996) and with other applicable 
regulatory requirements.
Confidentiality Statement
This confidential document is the property of AstraZeneca.  No unpublished information contained 
herein may be disclosed without prior written approval from AstraZeneca.  Access to this document 
must be restricted to relevant parties.
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
2 of 94
PROTOCOL SYNOPSIS
Title of the Study
A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess the Relative 
Bioavailability of 3 Different Extended-release Formulations of Verinurad in Healthy Subjects
Principal Investigator
Study Centre
This study will be conducted at a single study centre.
PAREXEL Early Phase Clinical Unit Berlin
On the premises of DRK Kliniken Berlin Westend, Haus 31
Spandauer Damm 130
14050 Berlin
Germany
Study Rationale
This study is intended to assess the relative bioavailability between the (extended-release) 
ER8 capsule formulation (used in study D5495C00002) given under fasted conditions and 
2 new capsule formulations of verinurad (A-capsule and B-capsule) given under fed or fasted 
conditions.  All three capsules target an 8-h release profile (extended-release).
The highest dose (12 mg) currently tested in patients will be tested in this study.  The study is 
designed to provide information to optimize the verinurad part of a fixed dose combination 
capsule to be used in future development.
Number of Subjects Planned
Twenty-five (25) subjects will be randomised to ensure at least 20 evaluable subjects at the 
end of the last treatment period.
Study Period
Estimated date of first subject enrolled:
June 2019 (signing of informed consent)
Estimated date of last subject completed:
September 2019 (last subject, last visit)
Study Objectives
Primary Objective:
x
To evaluate the relative bioavailability between the A-capsule and B-capsule formulations 
under both fed and fasted conditions with the ER8 capsule formulation under fasted 
conditions and with each other under the same food conditions.
Secondary Objectives:
x
To evaluate the relative bioavailability between fed and fasted conditions for the
A-capsule and B-capsule formulations as well as between the A-capsule and B-capsule 
formulations.
PPD

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
3 of 94 
x 
To examine the pharmacokinetic (PK) profiles of verinurad when administered as the 
3 different capsule formulations under fasted conditions. 
x 
To assess the safety and tolerability of single doses of verinurad in healthy volunteers. 
Study Design 
This study will be a randomised, open-label, single-dose, 5-period, 5-treatment, crossover 
study in healthy male and female subjects, performed at a single study centre. 
The study will comprise of: 
x 
A screening period of maximum 28 days; 
x 
Five treatment periods during which subjects will be resident from the morning of the day 
before dosing with verinurad (Day -1) until at least 72 hours after dosing; discharged on 
the morning of Day 4 of each treatment period; and 
x 
A Follow-up Visit within 7 to 14 days after the last administration of verinurad. 
x 
There will be a minimum washout period of 5 days between each dose administration. 
A total of 25 healthy male and female subjects will be randomised into this study.  Each 
subject will receive 5 single-dose treatments of 12 mg verinurad with 240 mL water, 
following an overnight fast of at least 10 hours or following a high-fat, high-calorie breakfast 
(after the overnight fast): 
x 
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted. 
x 
Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted. 
x 
Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed. 
x 
Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted. 
x 
Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed. 
For both the fasted and fed dosing, no fluids will be allowed apart from water which can be 
given until 1 hour prior and 1 hour after administration of verinurad, water to be given with 
the verinurad administration and the beverages provided with the high-fat, high-calorie 
breakfast in dosing periods with administration under fed conditions.  All subjects will be 
instructed to drink approximately 2 L to 2.5 L of liquid a day (including Day -1) throughout 
the duration of the study. 
All subjects will follow an overnight fast of at least 10 hours before the dosing procedures on 
Day 1: for the fed dosing, a high-fat, high-calorie standard breakfast will be provided 
30 minutes before the administration of verinurad, to be consumed in full at least 5 minutes 
before dosing; for the fasted dosing, no breakfast will be served, and subjects will remain 
fasted.  A meal can be given 4 hours after administration of verinurad for both dosing 
conditions. 
 
Expected Duration of the Study 
The duration of the study is expected to be approximately 9 weeks for each individual subject 
(including the 28-day screening period). 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
4 of 94 
Targeted Study Population 
This study will be conducted in healthy male and female subjects, 18 to 50 years of age 
(inclusive) with a body mass index (BMI) between 18 and 30 kg/m2 (inclusive). 
 
Investigational Medicinal Product 
Supplier: 
AstraZeneca 
Formulation: 
Verinurad ER8 capsule formulation 
Verinurad A-capsule formulation 
Verinurad B-capsule formulation 
Strength/concentration: 
12 mg: ER8 capsule formulation 
6 mg: A-capsule formulation 
6 mg B-capsule formulation 
Dose: 
12 mg 
Route of administration: 
Oral 
Regimen: 
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted. 
Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted. 
Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed. 
Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted. 
Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed. 
 
Outcome Endpoints 
Pharmacokinetic Endpoints: 
Serial venous blood samples will be obtained for the determination of verinurad in plasma.  
Samples will be collected, labelled, stored and shipped as detailed in the Laboratory Manual. 
x 
Primary PK parameters: area under plasma concentration-time curve from zero to infinity 
(AUC), AUC from time 0 to the last quantifiable concentration (AUC0-t), and maximum 
observed plasma concentration (Cmax). 
x 
Secondary PK parameters: AUC from time 0 to 24 hours post dose (AUC0-24), time to 
reach maximum observed plasma concentration (tmax), associated half-life (t½Oz), 
apparent total body clearance of drug from plasma after extravascular administration 
(CL/F), mean residence time of the unchanged drug in the systemic circulation from zero 
to infinity (MRT), time of last quantifiable plasma concentration (tlast), volume of 
distribution at steady state (intravenous dosing) (Vss/F), and apparent volume of 
distribution during the terminal phase after extravascular administration (Vz/F). 
Additional PK parameters may be determined where appropriate. 
 
Safety and Tolerability Endpoints: 
Safety and tolerability variables will include 
x 
Adverse events (AEs) 
x 
Vital signs (systolic and diastolic blood pressure [BP], pulse rate) 
x 
12-lead electrocardiograms (ECGs) 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
5 of 94 
x 
Physical examination 
x 
Laboratory assessments (haematology, clinical chemistry and urinalysis). 
Viral serology and drugs of abuse, alcohol and cotinine will be assessed for eligibility, 
follicle-stimulating hormone (females only), pregnancy testing (females only) and use of 
concomitant medication will also be assessed and reported. 
 
Statistical Methods 
Presentation and Analysis of Pharmacokinetic Data: 
Pharmacokinetic parameters will be summarized for each treatment using descriptive 
statistics.  The descriptive statistics may include: n, geometric mean, geometric coefficient of 
variation, arithmetic mean, arithmetic standard deviation (SD), median, minimum and 
maximum. The ratios of Cmax, AUC0-t and AUC will be calculated for the Test treatments to 
those of Reference treatment as well as the fed versus fasted conditions of the test products in 
each individual comparison.  For tmax, only n, median, minimum and maximum will be 
presented. 
Analyses will be performed using a linear fixed-effects analysis of variance model using the 
natural logarithm of AUC, AUC0-t and Cmax as the response variables, sequence, period and 
treatment as fixed-effects, subject nested within sequence as a random effect).  Transformed 
back from the logarithmic scale, geometric means together with confidence intervals (CIs) 
(2-sided 95%) for AUC, AUC0-t, and Cmax will be calculated and presented.  Also, ratios of 
geometric means together with CIs (2-sided 90%) will be estimated and presented.  
Additionally, the 90% CI for the difference in tmax will be calculated and presented. 
The following comparisons of relative bioavailability (AUC, AUC0-t and Cmax) of verinurad 
will be performed: 
x 
Treatment 2 versus 1 i.e., “A capsule, fasted” versus “ER8 capsule, fasted” 
x 
Treatment 4 versus 1 i.e., “B capsule, fasted” versus “ER8 capsule, fasted” 
x 
Treatment 3 versus 1 i.e., “A capsule, fed” versus “ER8 capsule, fasted” 
x 
Treatment 5 versus 1 i.e., “B capsule, fed” versus “ER8 capsule, fasted” 
x 
Treatment 4 versus 2 i.e., “B capsule, fasted” versus “A capsule, fasted” 
x 
Treatment 5 versus 3 i.e., “B capsule, fed” versus “A capsule, fed” 
x 
Treatment 3 versus 2 i.e., “A capsule, fed” versus “A capsule, fasted” 
x 
Treatment 5 versus 4 i.e., “B capsule, fed” versus “B capsule, fasted” 
Presentation and Analysis of Safety and Eligibility Data: 
Safety data (scheduled and unscheduled) will be presented in the data listings.  Continuous 
variables will be summarized using descriptive statistics (n, mean, SD, minimum, median, 
maximum) by treatment.  Categorical variables will be summarized in frequency tables 
(frequency and proportion) by treatment.  The analysis of the safety variables will be based on 
the safety analysis set. 
Tabulations and listings of data for vital signs, clinical laboratory tests and ECGs, will be 
presented.  Any new or aggravated clinically relevant abnormal medical physical examination 
finding compared to the baseline assessment will be reported as an AE.  Data will be 
summarized for the observed values at each scheduled assessment, together with the 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
6 of 94
corresponding changes (and/or percentage change) from the baseline when baseline is defined.  
Clinical laboratory data will be reported in the units provided by the clinical laboratory and in 
Système International units in the Clinical Study Report.
Out-of-range values for safety laboratory, vital signs and ECG will be flagged in individual 
listings as well as summarized descriptively using agreed standard reference ranges and/or 
extended reference ranges (e.g., AZ, program or laboratory ranges).
Determination of Sample Size
Twenty-five (25) subjects will be equally randomised to 5 treatment sequences: 12345, 23451,
51234, 34512 and 45123 in order to ensure at least 20 evaluable subjects at the end of the last 
treatment period.
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
7 of 94 
PROTOCOL AMENDMENTS 
Protocol Amendment No. 1 Dated 24 June 2019 
The following changes were made to the original Clinical Study Protocol, Final 1.0, dated 
06 May 2019 to include changes requested by the Bundesinstitut für Arzneimittel und 
Medizinprodukte (BfArM) and a few additional minor corrections to the text were made. 
1. The Schedule of Assessments (Table 5-2) were updated to include body weight, height 
and BMI calculation indicated at the Screening Visit. 
2. Exclusion criteria #5 (Section 7.1.2) was updated to match the previous study 
(D5495C00006) with lesser restriction on exclusion heartrate criteria and the lower limit 
to the diastolic blood pressure was added. 
3. Exclusion criteria #9 (Section 7.1.2) was updated with more detail on the excessive 
alcohol consumption criteria for exclusion. 
4. Exclusion criteria #16 (Section 7.1.2) was updated with more detail on the excessive 
caffeine consumption criteria for exclusion. 
5. Section 8, Study Stopping Rules were updated with more confirmatory wording (e.g., 
“may” changed to “must”). 
6. The details of the Food and Drug Administration approved breakfast (Section 9.6.1) were 
corrected and updated according to the site specifications. 
7. Standalone urea was removed from the Serum Clinical Chemistry panel (Section 10.3.5.2).  
Considering a conversation factor of 1.0, the urea concentration indicated in mmol/L is 
identical to the blood urea nitrogen (BUN) concentration indicated in mmol/L.  Therefore, 
urea measurement was removed from the panel and only BUN was kept. 
8. Details were clarified on reporting appropriate clinically significant changes from baseline 
to safety parameters as adverse events during the study (Section 13.2.6). 
 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
8 of 94 
1. 
TABLE OF CONTENTS 
PROTOCOL SYNOPSIS .......................................................................................................... 2 
PROTOCOL AMENDMENTS ................................................................................................. 7 
Protocol Amendment No. 1 Dated 24 June 2019 ...................................................................... 7 
1. 
TABLE OF CONTENTS ....................................................................................... 8 
1.1. 
List of Tables ........................................................................................................ 12 
1.2. 
List of Figures ....................................................................................................... 12 
2. 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ......................... 13 
3. 
ETHICAL AND REGULATORY REQUIREMENTS ....................................... 17 
3.1. 
Ethical Conduct of the Study ................................................................................ 17 
3.2. 
Subject Data Protection ........................................................................................ 17 
3.3. 
Ethics and Regulatory Review.............................................................................. 17 
3.4. 
Insurance ............................................................................................................... 18 
3.5. 
Informed Consent ................................................................................................. 18 
3.6. 
Changes to the Protocol and Informed Consent Form.......................................... 18 
4. 
INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ........... 19 
5. 
INTRODUCTION ................................................................................................ 22 
5.1. 
Background Information ....................................................................................... 22 
5.2. 
Investigational Medicinal Product Information .................................................... 23 
5.2.1. 
Description of Verinurad ...................................................................................... 23 
5.2.2. 
Pre-clinical Findings ............................................................................................. 23 
5.2.3. 
Clinical Studies ..................................................................................................... 24 
5.2.3.1. 
Safety Profile ........................................................................................................ 24 
5.2.3.2. 
Pharmacokinetics .................................................................................................. 26 
5.3. 
Study Rationale and Justification of Study Design .............................................. 26 
5.3.1. 
Study Rationale ..................................................................................................... 26 
5.3.2. 
Overall Study Design ............................................................................................ 26 
5.3.2.1. 
End of Study ......................................................................................................... 27 
5.3.2.2. 
Expected Duration of the Study ............................................................................ 27 
5.3.3. 
Study Flow Chart and Schedule of Assessments .................................................. 28 
5.3.4. 
Total Blood Volume ............................................................................................. 33 
5.3.5. 
Order of Assessments ........................................................................................... 33 
5.4. 
Dose Rationale ...................................................................................................... 33 
5.5. 
Risk-benefit Assessment ....................................................................................... 33 
6. 
STUDY OBJECTIVES ........................................................................................ 35 
6.1. 
Primary Objective ................................................................................................. 35 
6.2. 
Secondary Objectives ........................................................................................... 35 
7. 
SELECTION OF STUDY POPULATION AND RESTRICTIONS ................... 36 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
9 of 94 
7.1. 
Selection of Study Population .............................................................................. 36 
7.1.1. 
Inclusion Criteria .................................................................................................. 36 
7.1.2. 
Exclusion Criteria ................................................................................................. 37 
7.2. 
Restrictions During the Study ............................................................................... 39 
7.2.1. 
Reproductive Restrictions ..................................................................................... 40 
7.2.1.1. 
Female Subjects .................................................................................................... 40 
7.2.1.2. 
Male Subjects........................................................................................................ 41 
7.3. 
Replacement of Subjects....................................................................................... 42 
8. 
STUDY STOPPING RULES ............................................................................... 43 
8.1. 
Discontinuation of Investigational Medicinal Product and Withdrawal from the 
Study ..................................................................................................................... 43 
8.2. 
Premature Termination of the Study and Stopping Criteria ................................. 43 
9. 
TREATMENTS .................................................................................................... 45 
9.1. 
Identity of the Investigational Medicinal Product ................................................ 45 
9.2. 
Supply of Investigational Medicinal Product ....................................................... 45 
9.3. 
Storage and Handling Procedures ......................................................................... 45 
9.4. 
Labelling ............................................................................................................... 46 
9.5. 
Drug Accountability, Dispensing and Destruction ............................................... 46 
9.6. 
Dose and Treatment Regimens ............................................................................. 46 
9.6.1. 
FDA Breakfast Menu ............................................................................................ 47 
9.7. 
Concomitant and Post-study Treatments .............................................................. 47 
9.8. 
Treatment Compliance.......................................................................................... 47 
9.9. 
Randomization ...................................................................................................... 48 
9.9.1. 
Subject Enrolment and Randomization ................................................................ 48 
9.9.2. 
Procedures for Randomization ............................................................................. 48 
9.9.3. 
Procedures for Handling Incorrectly Randomised Subjects ................................. 49 
9.10. 
Blinding ................................................................................................................ 49 
10. 
MEASUREMENTS AND METHODS OF ASSESSMENTS ............................. 50 
10.1. 
Appropriateness of Measurements ....................................................................... 50 
10.2. 
Pharmacokinetics .................................................................................................. 50 
10.2.1. 
Sample Collection and Handling .......................................................................... 50 
10.2.2. 
Pharmacokinetic Drug Assays .............................................................................. 50 
10.3. 
Safety and Eligibility Measurements .................................................................... 50 
10.3.1. 
Adverse Events ..................................................................................................... 50 
10.3.2. 
Vital Signs ............................................................................................................ 51 
10.3.3. 
Electrocardiograms ............................................................................................... 51 
10.3.4. 
Physical Examination ........................................................................................... 51 
10.3.5. 
Laboratory Assessments ....................................................................................... 52 
10.3.5.1. 
Haematology ......................................................................................................... 52 
10.3.5.2. 
Serum Clinical Chemistry..................................................................................... 52 
10.3.5.3. 
Urinalysis .............................................................................................................. 52 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
10 of 94 
10.3.5.4. 
Pregnancy Testing ................................................................................................ 52 
10.3.5.5. 
Viral Serology ....................................................................................................... 53 
10.3.5.6. 
Drugs of Abuse, Alcohol and Cotinine................................................................. 53 
10.3.6. 
Concomitant Medication ...................................................................................... 53 
10.4. 
Procedures for Handling of Biological Samples .................................................. 53 
10.4.1. 
Storage and Destruction of Biological Samples ................................................... 53 
10.4.1.1. 
Pharmacokinetic Samples ..................................................................................... 53 
10.4.2. 
Labelling and Shipment of Biohazard Samples.................................................... 54 
10.4.3. 
Chain of Custody of Biological Samples.............................................................. 54 
10.4.4. 
Withdrawal of Informed Consent for Donated Biological Samples ..................... 54 
11. 
DATA QUALITY ASSURANCE AND DATA MANAGEMENT .................... 55 
11.1. 
Quality Control and Source Data Verification ..................................................... 55 
11.2. 
Audit/Inspections .................................................................................................. 55 
11.3. 
Study Monitoring .................................................................................................. 55 
11.4. 
Data Collection ..................................................................................................... 55 
11.4.1. 
Case Report Forms and Source Documents ......................................................... 56 
11.4.2. 
Access to Source Documents................................................................................ 56 
11.5. 
Data Management ................................................................................................. 56 
12. 
STATISTICAL METHODS ................................................................................. 58 
12.1. 
Overview............................................................................................................... 58 
12.2. 
General Statistical Methodology .......................................................................... 58 
12.2.1. 
Missing Data ......................................................................................................... 59 
12.3. 
Study Populations ................................................................................................. 59 
12.3.1. 
Safety Analysis Set ............................................................................................... 59 
12.3.2. 
Pharmacokinetic Analysis Set .............................................................................. 59 
12.4. 
Determination of Sample Size .............................................................................. 60 
12.5. 
Protocol Deviations .............................................................................................. 60 
12.6. 
Subject Disposition ............................................................................................... 61 
12.7. 
Demographic and Baseline Data .......................................................................... 61 
12.8. 
Prior and Concomitant Medication and Drug Administration ............................. 62 
12.8.1. 
Prior and Concomitant Medication ....................................................................... 62 
12.8.2. 
Drug Administration ............................................................................................. 62 
12.9. 
Pharmacokinetic Analysis .................................................................................... 62 
12.9.1. 
Pharmacokinetic Parameters ................................................................................. 62 
12.9.2. 
Derivation of Pharmacokinetic Parameters .......................................................... 63 
12.9.3. 
Presentation of Pharmacokinetic Data .................................................................. 65 
12.9.4. 
Statistical Analysis of Pharmacokinetic Data ....................................................... 68 
12.10. 
Analysis of Safety Data ........................................................................................ 68 
12.10.1. 
Adverse Events ..................................................................................................... 69 
12.10.2. 
Vital Signs ............................................................................................................ 70 
12.10.3. 
Resting 12-lead Electrocardiogram ...................................................................... 70 
12.10.4. 
Physical Examination ........................................................................................... 71 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
11 of 94 
12.10.5. 
Laboratory Assessments ....................................................................................... 71 
13. 
ADVERSE EVENTS ........................................................................................... 72 
13.1. 
Definitions ............................................................................................................ 72 
13.1.1. 
Definition of Adverse Events ............................................................................... 72 
13.1.2. 
Definitions of Serious Adverse Event .................................................................. 72 
13.1.3. 
Other Significant Adverse Events ........................................................................ 72 
13.2. 
Recording of Adverse Events ............................................................................... 73 
13.2.1. 
Time Period for Collection of Adverse Events..................................................... 73 
13.2.2. 
Follow-up of Unresolved Adverse Events ............................................................ 73 
13.2.3. 
Variables ............................................................................................................... 73 
13.2.4. 
Causality Collection.............................................................................................. 74 
13.2.5. 
Adverse Events Based on Symptoms and Signs .................................................. 74 
13.2.6. 
Adverse Events Based on Examinations and Tests .............................................. 74 
13.2.7. 
Hy's Law ............................................................................................................... 75 
13.3. 
Reporting of Serious Adverse Events ................................................................... 75 
14. 
LEGAL AND ADMINISTRATIVE ASPECTS .................................................. 76 
14.1. 
Archiving of Study Documents ............................................................................ 76 
14.2. 
Publication of Study Results ................................................................................. 76 
14.3. 
Clinical Study Report ........................................................................................... 76 
15. 
REFERENCE LIST .............................................................................................. 77 
16. 
APPENDICES ...................................................................................................... 79 
16.1. 
Additional Safety Information .............................................................................. 79 
16.2. 
International Airline Transportation Association 6.2 Guidance Document ......... 82 
16.3. 
Actions Required in Cases of Increases in Liver Biochemistry and Evaluation 
of Hy’s Law .......................................................................................................... 84 
16.3.1. 
Introduction........................................................................................................... 84 
16.3.2. 
Definitions ............................................................................................................ 84 
16.3.3. 
Identification of Potential Hy’s Law Cases .......................................................... 85 
16.3.4. 
Follow-Up ............................................................................................................. 86 
16.3.4.1. 
Potential Hy’s Law Criteria not Met .................................................................... 86 
16.3.4.2. 
Potential Hy’s Law Criteria met ........................................................................... 86 
16.3.5. 
Review and Assessment of Potential Hy’s Law Cases ......................................... 86 
16.3.6. 
Laboratory Tests ................................................................................................... 87 
16.3.7. 
References............................................................................................................. 88 
16.4. 
Actions Required in Cases of a Renal-related or Urolithiasis Treatment-
emergent Adverse Event or a Serum Creatinine Elevation .................................. 89 
16.4.1. 
Signs and Symptoms Suggestive of Urolithiasis .................................................. 89 
16.4.2. 
Deterioration of Renal Function ........................................................................... 89 
17. 
SIGNATURES ..................................................................................................... 91 
17.1. 
Declaration of Sponsor or Responsible Medical Expert (Physician) ................... 91 
17.2. 
Declaration of Sponsor or Responsible Medical Expert (Biostatistician) ............ 92 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
12 of 94 
17.3. 
Declaration of the Principal Investigator .............................................................. 93 
17.4. 
Declaration of the Deputy Principal Investigator ................................................. 94 
 
1.1. 
List of Tables 
 
Table 5-1 
Expected Duration of Each Study Part ........................................................ 27 
Table 5-2 
Schedule of Assessments ............................................................................ 30 
Table 5-3 
Total Blood Volume .................................................................................... 33 
Table 6-1 
Primary Objective and Outcome Measures ................................................. 35 
Table 6-2 
Secondary Objectives and Outcome Measures ........................................... 35 
Table 9-1 
Identity of the Investigational Medicinal Product ....................................... 45 
 
 
1.2. 
List of Figures 
 
Figure 5-1 
Study Flow Chart ........................................................................................ 28 
 
 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
13 of 94
2.
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
Abbreviation or 
special term
Explanation
AE
Adverse event (see definition in Section 13.1.1)
ALT
Alanine aminotransferase
AST
Aspartate aminotransferase
AUC
Area under plasma concentration-time curve from zero to infinity
AUC0-t
Area under the plasma concentration-curve from time zero to time of last 
quantifiable concentration
AUC0-24
Area under the plasma concentration-time curve from time zero to 24 hours after 
dosing
%AUCextr
Percentage of AUC obtained by extrapolating the area under the plasma 
concentration-time curve from the time of the last quantifiable concentration to 
infinity
AV
Atrioventricular
BLQ
Below the limit of quantification
BMI
Body mass index
BP
Blood pressure
bpm
Beats per minute
CI
Confidence interval 
CKD
Chronic kidney disease
Clast
Drug concentration at last observed time point
CL/F
Apparent total body clearance of drug from plasma after extravascular 
administration
Cmax
Maximum observed plasma concentration
CRO
Contract research organization
CSP
Clinical study protocol
CSR
Clinical study report 
CV
Coefficient of variation
DMP
Data management plan
DVS
Data validation specification
ECG
Electrocardiogram
FDA
Food and Drug Administration
FSH
Follicle-stimulating hormone
gCV%
Geometric coefficient of variation
CCI
CCI
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
14 of 94 
Abbreviation or 
special term 
Explanation 
GGT 
Gamma glutamyl transpeptidase (transferase) 
gmean 
Geometric mean 
GMP 
Good Manufacturing Practice 
gSD 
Geometric standard deviation 
Hb 
Haemoglobin 
HBsAg 
Hepatitis B surface antigen 
HCT 
Haematocrit 
HIV 
Human immunodeficiency virus 
HL 
Hy’s Law 
IATA 
International Airline Transportation Association 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 
IMP 
Investigational medicinal product 
IUD 
Intrauterine device 
λz 
Terminal elimination rate constant 
λzN 
Number of data points included in the log-linear regression analysis 
LLOQ 
Lower limit of quantification 
max 
Maximum 
MedDRA 
Medical Dictionary for Regulatory Activities 
min 
Minimum 
MRT 
Mean residence time 
ms 
milliseconds 
N 
Number of subjects 
NA 
Not applicable 
NC 
Not calculable 
ND 
Not determined 
NQ 
Non-quantifiable 
NR 
No result 
NS 
No sample 
OAE 
Other significant adverse events 
OTC 
Over-the-counter 
PD 
Pharmacodynamics 
PDF 
Portable Document Format 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
15 of 94 
Abbreviation or 
special term 
Explanation 
PDS 
Protocol deviation specification (document) 
PHL 
Potential Hy’s Law 
PI 
Principal Investigator 
PK 
Pharmacokinetics 
PR(PQ) 
ECG interval measured from the onset of the P wave to the onset of the QRS 
complex 
QP 
Qualified Person 
QRS 
ECG interval measured from the onset of the QRS complex to the J point 
QT 
ECG interval measured from the onset of the QRS complex to the end of the T 
wave 
QTcF 
QT interval corrected for heart rate using Fridericia’s formula 
R&D 
Research and Development 
RBC 
Red blood cell 
RR 
The time between corresponding points on 2 consecutive R waves on ECG 
Rsq_adj 
Regression coefficient adjusted for λzN, Goodness-of-fit statistic for calculation of 
λz 
SAE 
Serious adverse event (see definition in Section 13.1.2). 
SAP 
Statistical Analysis Plan 
SD 
Standard deviation 
SOC 
System Organ Class 
SOP 
Standard operating procedure 
SRC 
Safety Review Committee 
sUA 
Serum uric acid 
SUSAR 
Suspected unexpected serious adverse reaction 
t½Oz 
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-
time curve 
TCA 
Tricyclic anti-depressant 
TCS 
Tata Consultancy Services – an AstraZeneca partner who conduct data entry onto 
Sapphire 
tlast 
Time of last quantifiable plasma concentration 
t lower 
Start of exponential fit 
tmax 
Time to reach maximum observed plasma concentration 
t upper 
End of exponential fit 
UA 
Uric acid 
UK 
United Kingdom 
ULN 
Upper limit of normal 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
16 of 94 
Abbreviation or 
special term 
Explanation 
ULT 
Urate-lowering therapy 
USA 
United States of America 
uUA 
Urinary uric acid 
Vss/F 
Apparent volume of distribution at steady state 
Vz/F 
Apparent volume of distribution during the terminal phase after extravascular 
administration 
WBC 
White blood cell 
XO 
Xanthine oxidase 
XOI 
Xanthine oxidase inhibitor 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
17 of 94 
3. 
ETHICAL AND REGULATORY REQUIREMENTS 
3.1. 
Ethical Conduct of the Study 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki (version 1996) and are consistent with International Council for 
Harmonisation (ICH) Good Clinical Practice (GCP) and the AstraZeneca policy on Bioethics 
and Human Biological Samples. 
3.2. 
Subject Data Protection 
The Informed Consent Form (ICF) will incorporate (or, in some cases, be accompanied by a 
separate document incorporating) wording that complies with relevant data protection and 
privacy legislation. 
All clinical study findings and documents will be regarded as confidential.  The Principal 
Investigator (PI) and members of his/her research team must not disclose such information 
without prior written approval from the Sponsor. 
The anonymity of participating subjects must be maintained.  Subjects will be specified in 
outputs and other documents containing subject data by their subject number, not by name.  
Documents that identify the subject (e.g., signed ICF) will be maintained in confidence by the 
PI. 
Study data will be stored in accordance with local and global data protection laws. 
3.3. 
Ethics and Regulatory Review 
The study will be submitted to the national Regulatory Agency, Federal Institute for Drugs 
and Medical Devices (BfArM), for review and approval, by PAREXEL in accordance with 
local regulatory procedures. 
The study will be submitted to the Independent Ethics Committee (IEC) for ethical review and 
approval by the PI in accordance with local procedures. 
PAREXEL will provide the IEC and PI with safety updates/reports according to local 
requirements, including Suspected Unexpected Adverse Reactions (SUSARs), where relevant. 
AstraZeneca will provide the Regulatory Authority with safety updates/reports according to 
local requirements, including SUSARs, where relevant. 
Compensation will be reasonable and related to the nature and degree of inconvenience and 
discomfort as a result of participation in the study.  Information on how study subjects will be 
compensated is contained in the ICF. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
18 of 94 
3.4. 
Insurance 
The Sponsor has covered this clinical study by means of a insurance of the clinical study 
according to national requirements.  The name and address of the relevant insurance company, 
the certificate of insurance, the policy number and the sum insured are provided in the 
Investigator's Site File. 
3.5. 
Informed Consent 
The subjects shall be informed of the nature, significance, implications and risks of the trial, 
and informed consent will be freely given and evidenced in writing, dated and signed, or 
otherwise marked, by the subject as evidence to indicate his/her free informed consent, prior 
to the start of the study. 
The nature of the informed consent will comply with the Declaration of Helsinki (version 
1996), the current requirements of GCP (CPMP/ICH/135/95) and local regulation whichever 
offers the greater subject protection. 
3.6. 
Changes to the Protocol and Informed Consent Form 
Study procedures will not be changed without the mutual agreement of the PI and 
AstraZeneca. 
If there are any substantial changes to the study protocol, then these changes will be 
documented in a study protocol amendment and where required in a new version of the study 
protocol. 
If a protocol amendment requires a change to the ICF the IEC should approve the revised ICF 
before the revised form is used. 
If local regulations require, any administrative change will be communicated to or approved 
by the IEC. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
19 of 94
4.
INVESTIGATORS AND STUDY ADMINISTRATIVE 
STRUCTURE
Sponsor:
AstraZeneca AB
151 85 Södertälje
Sweden
Sponsor’s Lead Physician:
AstraZeneca R&D GothenBurg
Pepparedsleden 1
431 83 Mölndal
Sweden
Sponsor’s Biostatistician:
AstraZeneca,
Gaithersburg, MD 20878
United States of America
Principal Investigator:
PAREXEL Early Phase Clinical Unit Berlin
On the premises of DRK Kliniken Berlin Westend, Haus 31
Spandauer Damm 130
14050 Berlin
Germany
Deputy PI:
PAREXEL Early Phase Clinical Unit Berlin
On the premises of DRK Kliniken Berlin Westend, Haus 31
Spandauer Damm 130
14050 Berlin
Germany
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
20 of 94
Contract Research Organization (CRO):
PAREXEL Early Phase Clinical Unit Berlin
On the premises of Klinikum Westend, Haus 31
Spandauer Damm 130
14050 Berlin
Germany
Clinical Laboratory:
Synlab Clinical Trial GmbH
Turmstr. 21 (House M)
10559 Berlin
Germany
Contact:
Pharmacy:
Salzufer 13/14, 10587 Berlin,
Germany
Contact:
Analytical Laboratory:
(pharmacokinetic [PK] sample analysis)
Covance Bioanalytical Services, LLC
8211 SciCor Drive, Suite B
Indianapolis, IN 46214
United States of America
Contact:
Bioanalytical Chemistry
Covance Laboratories, Inc.
3301 Kinsman Blvd.
Madison, Wisconsin 53704
United States of America
PPD
PPD
PPD
PPD
PPD
PPD

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
21 of 94
Pharmacokineticist
Covance Clinical Development Services (CDS)
Clinical Pharmacology Services
Springfield House, Hyde Street, LS2 9LH, Leeds,
UK
Contact:
PAREXEL Laboratory Contact
PAREXEL International GmbH,
Spandauer Damm 130, 14050 Berlin, Germany
Contact:
Adverse Event Reporting:
AstraZeneca Patient Safety Data Entry Site
Tata Consultancy Services
A list and contact details of investigators and other key study team members are provided in 
the Project Plan in the electronic Investigator’s Site File.  A list of all participating 
investigators will be provided in the Clinical Study Report (CSR).
PPD
PPD
PPD

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
22 of 94 
5. 
INTRODUCTION 
5.1. 
Background Information 
Purines are essential building blocks in all living organisms as adenosine triphosphate, the 
cellular carrier of energy, is a purine, and purines and pyrimidines make up DNA and RNA, 
the bearers of genetic information.  Metabolism of endogenous and ingested purines results in 
the production of urate.  In contrast to many lower species, the human body is unable to 
metabolize urate further and therefore eliminates urate through excretion.  Urate is excreted 
primarily through the kidneys, but urate is also eliminated through excretion into the 
intestines, where urate can be degraded by the uricase activity in the intestinal microbiome to 
carbon dioxide (CO2) and allantoin [1]. 
Uric acid (UA) is the protonated form of urate and can also be found in the human body.  At 
physiological pH ≈1% of the circulating urate is in the form of UA, but in urine the fraction of 
excreted urate present in the form of UA increases with lower urinary pH. 
The level of urate in the circulation is determined by the balance between production and 
elimination.  At steady state, production and elimination are similar [1]. 
Pharmacological modification of the levels of urate is possible through multiple mechanisms.  
Inhibition of xanthine oxidase (XO), a key enzyme in the transformation of purines into urate, 
lowers serum urate by decreasing production.  Inhibition of URAT1, a key transporter 
responsible for reabsorption of urate from the primary urine in the proximal tubule, lowers 
serum urate by increasing renal excretion. Intravenous administration of drugs with uricase 
activity such as rasburicase, decreases serum urate by directly degrading urate. 
Hyperuricaemia (elevated levels of urate in the circulation) is a prerequisite for development 
of gout, an inflammatory arthritis caused by deposition of monosodium urate crystals in joints.  
Gout can occur in patients with serum urate > 6.8 mg/dL, which is the solubility limit of 
monosodium urate.  The prevalence of gout increases with higher serum urate [2].  Gout 
affects approximately 4% of the adult United States (US) population [3].  The prevalence of 
hyperuricaemia is higher than the prevalence of gout, as not all subjects with hyperuricaemia 
develop gout. 
Hyperuricaemia without clinical symptoms (e.g., gouty attack [acute gouty arthritis], gouty 
tophus, renal disorder) is called “asymptomatic hyperuricaemia” [4].  In the US and Europe, 
asymptomatic hyperuricaemia is not an approved indication for urate-lowering therapy (ULT).  
The Japanese and Chinese treatment guidelines propose that ULT should be considered for 
patients with asymptomatic hyperuricaemia with a serum uric acid (sUA) level of ≥ 8.0 mg/dL 
with complications (e.g., urinary calculus, renal disease, and hypertension) and ≥ 9.0 mg/dL 
without complications [5, 6]. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
23 of 94 
Evidence shows independent associations between elevated sUA and the risk of hypertension, 
myocardial infarction, heart failure, Chronic Kidney Disease (CKD), type 2 diabetes, and 
metabolic syndrome, including obesity [7, 8, 9, 10, 11].  Gout is associated with an increased 
risk of all-cause death, as well as CV death [12, 13, 14].  The causal relationship between 
elevated sUA and the aforementioned diseases and outcomes remains to be proven, however. 
Combination therapy with verinurad, a URAT1 inhibitor, and a xanthine oxidase inhibitor 
(XOI) such as allopurinol targets both excretion and production of UA, providing a dual 
mechanism approach that would effectively lower sUA and thereby potentially enable more 
patients to achieve and maintain target treatment goals to control their disease [15, 16, 17] and 
establish a potential causal relation between sUA lowering therapy and chronic kidney and 
cardiovascular disease. 
Potent URAT1 inhibition monotherapy has previously been associated with serum creatinine 
elevations.  Although the mechanism is yet to be proven, these URAT1 effects with 
monotherapy have been linked to increased concentrations of uric acid in the primary urine, 
which have the potential to induce uric acid crystallization in tubuli and collecting ducts. 
Based on these findings, verinurad will be exclusively developed as combination therapy, 
together with an XOI. This combination aims to provide a dual mechanism for lowering sUA 
and to reduce the risk of potential crystallization of UA in the renal tubules.  However, when 
necessary for the development, verinurad mono-therapy may be used in specific clinical 
studies applying appropriate safety monitoring and risk mitigation. 
The Investigator’s Brochure (IB) describes results from pre-clinical studies, clinical 
pharmacology studies, and clinical monotherapy and combination therapy with febuxostat or 
allopurinol. 
5.2. 
Investigational Medicinal Product Information 
5.2.1. 
Description of Verinurad 
Verinurad (also known as RDEA3170) is a potent and specific URAT1 inhibitor.  Uric acid 
transporter 1 is responsible for most of the reabsorption of filtered UA from the renal tubular 
lumen.  By inhibiting URAT1, verinurad increases urine uric acid (uUA) excretion and 
thereby lowers sUA. 
5.2.2. 
Pre-clinical Findings 
A series of pre-clinical studies were performed with results supporting clinical development of 
verinurad.  Overall, verinurad was well tolerated in the chronic rat and dog studies at high 
multiples of the exposures achieved at the highest doses tested in man.  No additive or new 
toxicity was observed in 13-week combination studies of verinurad and febuxostat or 
allopurinol in rats. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
24 of 94 
Verinurad was not genotoxic or carcinogenic based on results from the in vitro and in vivo 
batteries of genotoxicity tests and carcinogenicity studies in mice and rats.  Verinurad is not 
considered a reproductive hazard based on the results of reproductive toxicology studies and 
the lack of effects on reproductive organs in the 6- and 9-month studies in rats and dogs, 
respectively.  Verinurad is judged to not present a photosafety concern.  The 2 identified 
disproportionate human metabolites M1 and M8 have been assessed and qualified in Ames 
test, in a rabbit embryo-foetal development study and in a 3-month general oral dose toxicity 
study in the cynomolgus monkey. 
Further information on pre-clinical findings is available in the IB [18]. 
5.2.3. 
Clinical Studies 
Verinurad has been studied in healthy volunteers, subjects with gout, asymptomatic 
hyperuricemia and renally impaired patients.  As of 1 October 2018, a total of 831 subjects 
have received verinurad in 10 Phase 1 and 7 Phase 2 clinical studies (293 healthy subjects, 
63 subjects with renal impairment, and 507 subjects with gout or asymptomatic 
hyperuricaemia).  Verinurad alone has been given at multiple doses ranging from 2.5 mg to 
15 mg (given as the MR4 tablet).  Studies of verinurad in combination with an XOI have 
investigated verinurad doses ranging from 2.5 mg to 20 mg (MR4 tablet) where 20 mg of the 
MR4 tablet is comparable to 12 mg ER8 capsule. 
5.2.3.1. 
Safety Profile 
Healthy Subjects 
Safety was assessed in a pooled analysis of the completed Phase 1 studies in healthy subjects 
(101, 103, 104, 105, 106, 110, 111, and 112).  Collectively, these studies enrolled 293 male 
subjects treated at the following verinurad dose ranges: 53 received < 5 mg; 131 received 
5 mg to < 10 mg; 131 received 10 mg to 15 mg, and 30 received > 15 mg.  Overall, 94.5% 
completed the planned treatment. 
Adverse Events 
The incidence of AEs was similar among the pooled verinurad groups and pooled placebo 
groups.  Most AEs were RCTC toxicity Grade 1, and only 2 AEs were >Grade 2. The 2 higher 
severity AEs were Grade 3 blood creatinine increased and Grade 3 tooth infection, both in 
subjects dosed with verinurad in the 5 to < 10 mg range. There were no serious adverse events 
(SAEs).  Overall, 86 subjects (29.4%) experienced AEs.  The most common AE was 
headache, which occurred in 12 subjects (4.1%).  There was no apparent relationship between 
the incidence of these AEs and verinurad dose.  Three subjects withdrew from the study due to 
AEs: 2 subjects in Study 103 who had received verinurad 5 mg (dehydration and influenza, 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
25 of 94 
respectively) and 1 subject in Study 104 who had received verinurad 15 mg and experienced 
urticaria. 
Laboratory Evaluations 
In the pooled Phase 1 safety dataset, sCr elevations ≥ 1.25 × baseline and ≥ 1.5 × baseline 
were reported for 13.7% and 1.7% of subjects, respectively.  A change from baseline 
≥0.3 mg/dL was reported for 6.8% of all subjects.  There was no apparent relationship 
between sCr elevation and dose of verinurad. 
In the pooled dataset, 18.4% of all subjects treated with verinurad experienced ALT elevations 
≥ 1.5 × baseline, 5.1% experienced elevations ≥ 2.0 × baseline, and 2.0% experienced 
elevations ≥ 3.0 × baseline.  There was no clear relationship with dose.  Aspartate 
aminotransferase elevations ≥ 1.5 × baseline were reported for 6.1% of all subjects, while 
< 1.5% experienced AST elevations ≥ 2.0 or ≥ 3.0 × baseline. 
Vital signs, Physical findings, and Other Observations 
There were no clinically relevant or apparent dose-related post-treatment changes in vital 
signs.  Although transient changes in blood pressure, heart rate, and body temperature were 
noted at isolated timepoints for some subjects, none of these findings were judged to be 
clinically significant by the Investigator. 
Potential Effects on Electrocardiograms, Including Rate-corrected QT (QTc) Intervals 
In most of the Phase 1 studies in healthy subjects (Studies 103, 104, 105, 106, 110, 111, and 
112) there were no apparent treatment or dose-related trends in the 12-lead ECG parameters 
and no clinically important findings in the morphology of the 12-lead ECG for individual 
subjects.  However, in Study 101, prolongations in corrected QTcB (Bazett’s QTc correction) 
of > 60 msec occurred in 2 subjects in the 1 mg fasted dose group; yet, no subjects had 
prolonged QTcB intervals >450 msec.  Three subjects in the 1 mg fasted dose group and 
1 subject in the 5 mg fasted dose group had prolonged QTcF (Fridericia’s QTc correction) 
intervals (> 450 to 480 msec) although no subjects had a QTcF interval > 480 msec. All 
episodes of QTcF >450 msec occurred at heart rates < 50 bpm. 
Further information on clinical safety findings in healthy subjects is available in the IB [18]. 
Subjects with Gout or Asymptomatic Hyperuricemia 
Information on clinical safety findings in subjects with gout or asymptomatic hyperuricemia is 
available in the IB [18]. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
26 of 94 
5.2.3.2. 
Pharmacokinetics 
Following administration of verinurad as an extended-release capsule formulation (ER8), 
maximum plasma concentration (Cmax) occurs 4 hours after dosing.  Food did not affect 
verinurad exposure except for a 2-hour increase in tmax.  The degree of protein binding of 
verinurad in human plasma was 97%.  Glucuronidation is the major metabolic pathway of 
verinurad with oxidation as the minor pathway.  The major metabolites observed in humans 
after oral verinurad dosing are the acyl glucuronides M1 and M8 which are renally cleared.  
The amount of verinurad in urine is small (< 2% of given dose). The terminal half-life (t½) of 
verinurad was 13 hours in those with normal renal function and 21 hours in those with 
moderate renal impairment.  The exposure (area under the concentration-time curve [AUC] 
and maximum observed concentration [Cmax]) of verinurad increased in a dose-proportional 
manner and the accumulation was minimal after once daily dosing.  Subjects with moderate 
renal impairment have a < 1.6-fold higher verinurad exposure compared to those with normal 
renal function.  Japanese subjects have about a 1.5-fold higher exposure than Western 
subjects. 
Further information on PK findings is available in the Investigator’s Brochure [18]. 
5.3. 
Study Rationale and Justification of Study Design 
5.3.1. 
Study Rationale 
This study is intended to assess the relative bioavailability between the ER8 capsule 
formulation (used in study D5495C00002) given under fasted conditions and 2 new capsule 
formulation of verinurad (A-capsule and B-capsule) given under fed or fasted conditions.  All 
three capsules target an 8-h release profile (extended-release). 
The highest dose (12 mg) currently tested in patients will be tested in this study.  The study is 
designed to provide information to optimize the verinurad part of a fixed dose combination 
capsule to be used in future development. 
5.3.2. 
Overall Study Design 
This study will be a randomised, open-label, single-dose, 5-period, 5-treatment, crossover 
study in healthy male and female subjects, performed at a single study centre. 
The study will comprise: 
x 
A screening period of maximum 28 days; 
x 
Five treatment periods during which subjects will be resident from the morning of the day 
before dosing with verinurad (Day -1) until at least 72 hours after dosing; discharged on 
the morning of Day 4 of each Treatment Period; and 
x 
A Follow-up Visit within 7 to 14 days after the last administration of verinurad. 
x 
There will be a minimum washout period of 5 days between each dose administration. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
27 of 94 
A total of 25 healthy male and female subjects will be randomised into this study.  Each 
subject will receive five single-dose treatments of 12 mg verinurad with 240 mL water, 
following an overnight fast of at least 10 hours: 
x 
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted. 
x 
Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted. 
x 
Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed. 
x 
Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted. 
x 
Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed. 
For both the fasted and fed dosing, no fluids will be allowed apart from water which can be 
given until 1 hour prior and 1 hour after administration of verinurad, water to be given with 
the verinurad administration and beverages provided with the high-fat, high-calorie breakfast 
(see Section 9.6.1) in dosing periods with the administration under fed conditions.  All 
subjects will be instructed to drink approximately 2 L to 2.5 L of liquid a day (including Day -
1) throughout the duration of the study. 
Subjects will follow an overnight fast of at least 10 hours before the dosing procedures: for the 
fed dosing, a high-fat, high-calorie standard breakfast will be served 30 minutes before the 
planned administration of verinurad to be consumed in full at least 5 minutes before dosing; 
for the fasted dosing, no breakfast will be served.  A meal can be given 4 hours after 
administration of verinurad for both dosing states. 
5.3.2.1. 
End of Study 
The end of study is defined as the last subject’s last visit to the Clinical Unit. 
5.3.2.2. 
Expected Duration of the Study 
Each subject will be involved in the study for approximately 9 weeks (including the screening 
period). 
Table 5-1 
Expected Duration of Each Study Part 
Screening 
28 days before dose 
Treatment Periods 
5 treatment periods during which subjects will be resident at the 
Clinical Unit from the day before dosing (Day -1) until at least 
72 hours after dosing; discharged on Day 4 of each treatment period 
Washout Period 
At least 5 days between each dose administration 
Follow-up 
7 to 14 days after dose 
Total Duration 
Up to 63 days (9 weeks) 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
28 of 94 
5.3.3. 
Study Flow Chart and Schedule of Assessments 
The flow of events is illustrated in Figure 5-1 for all treatments, depending on the subject’s 
assigned randomization (refer to Section 9.9.2). 
The Schedule of Assessments displaying assessments/tasks and time points are presented in 
Table 5-2. 
Figure 5-1 
Study Flow Chart 
 
 
Visit 1 
Screening 
 
 
< 28 days  
 
 
 
 
Randomisation a 
Visit 2 
Treatment Period 1 b 
Treatment 1/2/3/4 or 5 
 
At least 5 days washout 
 
 
 
 
 
Visit 3 
Treatment Period 2 b 
Treatment 1/2/3/4 or 5 
 
 
At least 5 days washout 
 
 
 
 
 
Visit 4 
Treatment Period 3 b 
Treatment 1/2/3/4 or 5 
 
 
At least 5 days washout 
 
 
 
 
 
Visit 5 
Treatment Period 4 b 
Treatment 1/2/3/4 or 5 
 
 
At least 5 days washout 
 
 
 
 
 
 
Visit 6 
Treatment Period 5 b 
Treatment 1/2/3/4 or 5 
 
 
7-14 days after last verinurad dose 
 
 
 
 
 
 
Visit 7 
Follow-up 
 
 
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted.; 
Treatment 2: 2 x 6 mg verinurad A capsule formulation, fasted. 
Treatment 3: 2 x 6 mg verinurad A capsule formulation, fed. 
Treatment 4: 2 x 6 mg verinurad B capsule formulation, fasted. 
Treatment 5: 2 x 6 mg verinurad B capsule formulation, fed 
a 
Randomization on Day -1 of Treatment Period 1. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
29 of 94 
b 
Residential period.  Admission to Clinical Unit on Day -1, discharge from Clinical Unit on Day 4 
 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
30 of 94 
Table 5-2 
Schedule of Assessments 
 
Screening 
Treatment Periods 1, 2, 3, 4 and 5 
Follow-up Visit 
Corresponding 
Section in 
Protocol 
Visit 
1 
2, 3, 4, 5 and 6 
7 
Study Day 
Day -28 
to -2 
Day -1 
Day 1 to 4 
7 to 14 days 
post-final dose 
Inclusion/exclusion criteria 1 
X 
X 
 
 
Section 7.1 
Demographic data 
X 
 
 
 
Section 12.7 
Medical history 
X 
 
 
 
Section 12.8 
Urinary drug/alcohol screen 
X 
X 
 
 
Section 10.3.5.6 
Serology 
X 
 
 
 
Section 10.3.5.5 
Informed consent 
X 
 
 
 
Section 3.5 
Randomization 
 
X 2 
 
 
 
Study Residency: 
 
 
 
 
 
Check-in 
 
X 
(in the morning) 
 
 
Section 5.3.2 
Check-out 
 
 
Day 4 (after 72 h post-dose 
assessments) 
 
Section 5.3.2 
Non-residential visit 
X 
 
 
X 
Section 5.3.2 
Verinurad Administration: 
 
 
Day 1 (0 h) 
 
Section 5.3.2 and 
Section 9.6 
Safety and Tolerability: 
 
 
 
 
 
Adverse event questioning 3 
X 
X 
Spontaneous plus 
Day 1: pre-dose, 3 and 12 h post-dose 
Day 2: 24 h post-dose 
Day 3: 48 h post dose 
Day 4: 72 h post-dose 
X 
Section 10.3.1 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
31 of 94 
 
Screening 
Treatment Periods 1, 2, 3, 4 and 5 
Follow-up Visit 
Corresponding 
Section in 
Protocol 
Visit 
1 
2, 3, 4, 5 and 6 
7 
Study Day 
Day -28 
to -2 
Day -1 
Day 1 to 4 
7 to 14 days 
post-final dose 
Prior and concomitant 
medications questioning 
X 
X 
X 
X 
Section 9.7 
Blood pressure and pulse rate 
(supine) 
X 
X 
Day 1: Pre-dose 
Day 4: 72 h post-dose 
X 
Section 10.3.2 
Safety 12-lead 
Electrocardiograms 
X 
 
 
X 
Section 10.3.3 
Clinical laboratory 
evaluations 4 
X 
X 
 
X 
Section 10.3.5.1, 
Section 10.3.5.2 
and 
Section 10.3.5.3 
Physical examination 5 
X 
X(brief) 
Day 4: 72 h post-dose (brief) 
X (brief) 
Section 10.3.5.4 
Body weight and height, BMI 
X 
 
 
 
 
Pregnancy test 6 
X 
X 
 
X 
 
Pharmacokinetics 
 
 
 
 
 
Pharmacokinetic sampling for 
verinurad 
 
 
Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 
6, 8, 10 and 12 h post-dose 
Day 2: 24 and 36 h post-dose 
Day 3: 48 h post-dose 
Day 4: 72 h post-dose 
 
Section 10.2 
BMI = Body mass index. 
1 
To be reconfirmed on Day -1 of each treatment period. 
2 
Randomization to take place with admission to the unit on Day -1 of Treatment Period 1. 
3 
Adverse Events will be collected from the start of randomization throughout the treatment periods up to and including the Follow-up Visit.  Serious adverse 
events will be recorded from the time of informed consent. 
4 
Blood (clinical chemistry and haematology) and urine (urinalysis) sample collection.  Fasting samples: collected in the morning of admission following an 
overnight fast at home with no breakfast before admission.  Admission to take place in the morning to ensure fasted samples. 
Footnotes continues on next page 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
32 of 94 
5 
A complete physical examination should include general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose 
and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. 
A brief physical examination should include general appearance, skin, abdomen, cardiovascular system and respiratory; and any organ systems pertinent to the 
patient’s signs, symptoms or AEs. 
Full physical examination at screening and brief assessment at: admission to the first treatment period, 72 hours post each dose and at the Follow-up Visit. 
6 
Serum pregnancy test at screening, urine pregnancy test at admission to each treatment period and the Follow-up Visit. 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
33 of 94 
5.3.4. 
Total Blood Volume 
The approximate total amount of blood to be collected from each subject in this study, 
excluding repeat samples, is summarized in Table 5-3. 
Table 5-3 
Total Blood Volume 
 
Volume per Sample 
Number of Samples 
Total 
Clinical Laboratory: 
 
 
 
Haematology 
2.7 mL 
7 
18.9 mL 
Clinical chemistry a 
7.5 mL 
7 
52.5 mL 
Pharmacokinetics: 
 
 
 
Verinurad sampling 
2 mL 
80 
160 mL 
Total 
231.4 mL 
a 
When applicable, serology, serum pregnancy (females only) and follicle stimulating hormone analyses will 
be performed on the sample collected for clinical chemistry analyses. 
Repeat blood samples may be collected for safety reasons.  The maximum volume to be 
drawn from each subject must not exceed 500 mL. 
5.3.5. 
Order of Assessments 
It is important that PK sampling occurs as close as possible to scheduled time.  In order to 
achieve this, other assessments scheduled at the same time may be initiated prior to the time 
point. 
The sequence at a particular time point is: 
1 
Electrocardiograms (ECGs) 
2 
Vital signs (systolic and diastolic BP and pulse rate) 
3 
Pharmacokinetic blood sampling (will be drawn at the specified time point) 
5.4. 
Dose Rationale 
The highest dose (12 mg) currently tested in patients will be tested in this study. 
5.5. 
Risk-benefit Assessment 
There are no direct benefits for the subjects participating in this study.  However, 
study-related health assessments are provided without costs for the subjects.  The major risks 
for subjects who participate in the study will come from verinurad administration. 
In the current study, verinurad will be administered as a standalone therapy as a single dose in 
this 5-period-5-treatment crossover study. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
34 of 94
The main safety concern noted with verinurad monotherapy in healthy subjects is creatinine 
elevations > 1.5 x baseline which occurred in
% of healthy subjects. A change from 
baseline of ≥0.3 mg/dL was reported for
 of all subjects.  There was no apparent 
relationship between sCr elevation and dose of verinurad. The creatinine elevations were 
primarily transient, and often resolved despite continued dosing with verinurad. Further 
information is provided in the Investigator’s Brochure (IB) [18].
Providing add-on therapy with an XOI to participating subjects to minimize creatinine 
elevations was judged to be inappropriate in this study as the risk of significant and enduring 
creatinine elevations is estimated to be lower than the risk of developing toxicities to an XOI, 
some of which can be severe.  Instead, the risk of creatinine elevations will be minimized by 
ensuring participating subjects are properly hydrated, and by excluding patients from study 
inclusion as appropriate.
Overall, the study has been designed to minimize the risks to participating subjects by 
excluding subjects at high-risk of AEs and by applying appropriate safety monitoring of 
recruited study subjects.  The dose selected has been carefully considered in light of the target 
subject population.  The potential benefits of developing a new treatment for chronic kidney 
disease with hyperuricemia, therefore, outweigh the limited risks to the subjects exposed to 
treatment with verinurad in this study.
CCI
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
35 of 94 
6. 
STUDY OBJECTIVES 
6.1. 
Primary Objective 
Table 6-1 
Primary Objective and Outcome Measures 
Primary Objective 
Outcome Measures 
x 
To evaluate the relative bioavailability 
between the A-capsule and B-capsule 
formulations under both fed and fasted 
conditions with the ER8 capsule 
formulation under fasted conditions and 
with each other under the same food 
conditions. 
x 
Primary pharmacokinetic parameters: 
AUC, AUC0-t, and Cmax 
6.2. 
Secondary Objectives 
Table 6-2 
Secondary Objectives and Outcome Measures 
Secondary Objectives 
Outcome Measures 
x 
To evaluate the relative bioavailability 
between fed and fasted conditions for the 
A-capsule and B-capsule formulations as 
well as between the A-capsule and 
B-capsule formulations. 
x 
Primary pharmacokinetic parameters: 
AUC, AUC0-t, and Cmax 
x 
To examine the PK profiles of verinurad 
when administered as the 3 different 
capsule formulations under fasted 
conditions. 
x 
Primary pharmacokinetic parameters: 
AUC, AUC0-t, and Cmax 
x 
Secondary pharmacokinetic parameters: 
AUC0-24, tmax, t½Oz, CL/F, MRT, 
tlast, Vss/F, and Vz/F 
x 
To assess the safety and tolerability of 
single doses of verinurad in healthy 
volunteers 
x 
Adverse events, vital signs (systolic and 
diastolic BP, pulse rate), resting 12-lead 
ECGs, physical examination, and 
laboratory assessments (haematology, 
clinical chemistry and urinalysis) 
Refer to Section 12.9.1 for PK parameters and Section 10.3 for safety variables. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
36 of 94 
7. 
SELECTION OF STUDY POPULATION AND RESTRICTIONS 
7.1. 
Selection of Study Population 
The PI should keep a subject screening log of all potential subjects who consented and were 
subjected to screening procedures. 
Subjects who fail to meet all the inclusion criteria, or who do meet any exclusion criterion 
should not, under any circumstances, be randomised into the study.  There can be no 
exceptions to this rule. 
This study will be conducted in male and female subjects.  The study may not necessarily be 
balanced regarding gender.  The study was not formally powered to detect differences 
between genders for the primary endpoint.  It is not planned to perform sub-analyses on 
gender. 
7.1.1. 
Inclusion Criteria 
For inclusion in the study subjects should fulfil the following criteria: 
1 
Provision of signed and dated, written informed consent prior to any study specific 
procedures. 
2 
Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for 
cannulation or repeated venepuncture. 
3 
Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and weigh at least 
50 kg and no more than 100 kg (inclusive). 
4 
Females must have a negative pregnancy test at screening and on admission to the unit 
and must be: 
(1) not pregnant or currently lactating or breastfeeding. 
(2) of non-childbearing potential (as defined in Section 7.2.1.1.1), confirmed at screening 
by fulfilling one of the following criteria: 
(i) postmenopausal defined as amenorrhoea for at least 12 months or more 
following cessation of all exogenous hormonal treatments and FSH levels in the 
postmenopausal range (FSH levels > 40 IU/mL). 
(ii) documentation of irreversible surgical sterilization by hysterectomy, bilateral 
oophorectomy or bilateral salpingectomy but not tubal ligation. 
(3) OR if of childbearing potential (as defined in Section 7.2.1.1.2) must be willing to 
use an acceptable method of contraception (as described in Section 7.2.1.1.2) to avoid 
pregnancy for the entire study period. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
37 of 94 
7.1.2. 
Exclusion Criteria 
Subjects will not enter the study if any of the following exclusion criteria are fulfilled: 
1 
History of gout or any clinically significant disease or disorder which, in the opinion of 
the PI, may either put the volunteer at risk because of participation in the study, or 
influence the results or the volunteer’s ability to participate in the study. 
2 
Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of 
the first administration of verinurad. 
3 
History or presence of gastrointestinal (GI), hepatic or renal disease, or any other 
condition known to interfere with absorption, distribution, metabolism, or excretion of 
drugs. 
4 
Any clinically important abnormalities in clinical chemistry, haematology or urinalysis 
results as judged by the Investigator at screening and first admission, including: 
(1) Alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN), 
(2) Aspartate aminotransferase (AST) > 1.5 x ULN, 
(3) Bilirubin (total) > 1.5 x ULN, 
(4) Gamma glutamyl transpeptidase (GGT) > 1.5 x ULN. 
(5) If any of these tests are out-of-range, the tests can be repeated once. 
5 
Any clinically significant abnormal findings in vital signs at the Screening Visit and/or 
admission to the Clinical Unit, including, but not limited to, any of the following: 
(1) Heart rate (resting, supine) < 50 beats per minute (bpm) or > 85 bpm, 
(2) Systolic BP < 90 mmHg or > 140 mmHg and/or diastolic BP < 50 mmHg or 
> 90 mmHg sustained for > 10 min while resting in a supine position. 
6 
Any clinically significant abnormalities on 12-lead ECG at the Screening Visit, including, 
but not limited to any of the following: 
(1) QTcF > 450 ms or < 340 ms or family history of long QT syndrome, 
(2) Any significant arrhythmia, 
(3) Conduction abnormalities: 
(4) Clinically significant PR (PQ) interval prolongation (> 240 ms); intermittent second 
or third degree atrioventricular (AV) block, or AV dissociation, 
(5) Complete bundle branch block and/or QRS duration > 120 ms. 
7 
Any positive result at the Screening Visit for serum hepatitis B surface antigen or 
antiHBc antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) 
antibody. 
8 
Suspicion or known Gilbert’s and/or Lesch-Nyhan syndrome. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
38 of 94 
9 
Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as 
judged by the PI.  Excessive intake of alcohol defined as the regular consumption of more 
than 24 g of alcohol per day for men or 12 g of alcohol per day for women.  
10 Has received another new chemical entity (defined as a compound which has not been 
approved for marketing in the US) within 30 days or at least 5 half-lives (whichever is 
longer) of the first administration of verinurad in this study. 
Note: subjects consented and screened, but not randomised in this study or a previous 
Phase I study, are not excluded. 
11 Subjects who have previously received verinurad. 
12 Plasma donation within 1 month of screening or any blood donation/loss of more than 
500 mL during the 3 months prior to the Screening Visit. 
13 Subjects who are pregnant, lactating or planning to become pregnant. 
14 History of severe allergy/hypersensitivity or ongoing clinically relevant 
allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a 
similar chemical structure or class to verinurad. 
15 Current smokers or those who have smoked or used nicotine products (including 
e-cigarettes) within the 3 months prior to screening. 
16 Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as 
judged by the PI.  Excessive intake of caffeine defined as regular consumption of more 
than 600 mg of caffeine per day (e.g., > 5 cups of coffee) or would likely be unable to 
refrain from the use of caffeine-containing beverages during confinement at the 
investigational site. 
17 Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or positive 
screen for alcohol, drugs of abuse and cotinine on each admission to the study centre. 
18 Use of drugs with enzyme-inducing properties such as St John’s Wort within 3 weeks 
prior to the first administration of verinurad. 
19 Use of any prescribed or non-prescribed medication including antacids, analgesics (other 
than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 
600 times the recommended daily dose) and minerals during the 2 weeks prior to the first 
administration of verinurad or longer if the medication has a long half-life.  
The use of hormonal contraception therapy and hormonal replacement therapy for 
females are permitted. 
20 Any AstraZeneca, PAREXEL or study site employee or their close relatives 
21 Subjects who cannot communicate reliably with the PI and/or is not able to read, speak 
and understand the German language. 
22 Judgment by the PI that the subject should not participate in the study if they have any 
ongoing or recent (i.e., during the screening period) minor medical complaints that may 
interfere with the interpretation of study data or are considered unlikely to comply with 
study procedures, restrictions, and requirements. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
39 of 94 
23 Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, 
trusteeship, or committed to an institution by governmental or juridical order. 
24 Subjects with any special dietary restrictions such as subjects that are lactose intolerant or 
are vegetarians/vegans. 
7.2. 
Restrictions During the Study 
The following restrictions apply for the specified times during the study period: 
1 
Prior to Day 1 in each treatment period, all subjects will fast for 10 hours overnight before 
the morning dose procedures.  No fluids will be allowed apart from water which can be 
given until 1 hour before verinurad administration and then from 1 hour after verinurad 
administration, beverages provided with the high-fat breakfast in periods with dosing 
under fed conditions and water given during administration.  Verinurad will be 
administered with 240 mL of water on Day 1 of each treatment period under either fasted 
or fed conditions.  All subjects will be instructed to drink approximately 2 L to 2.5 L of 
liquid a day (including Day -1) during the entire study. 
During fed dosing, subjects will be provided with a Food and Drug Administration (FDA) 
high-fat, high-calorie breakfast 30 minutes before the scheduled dosing time (following 
the overnight fast as above), subjects should consume the breakfast within 25 minutes and 
finish the breakfast approximately 5 min before the scheduled dosing.  During the fasted 
dosing, subjects will remain fasted for dosing.  For both dosing states, no food will be 
allowed for at least 4 hours after dosing. 
2 
Subjects should not engage in any strenuous activity from 72 hours prior to check-in 
(Day -1 of Treatment Period 1) until after their Follow-up Visit. 
3 
Subjects should abstain from alcohol for the duration of the study from the first check-in 
(Day -1 of Treatment Period 1) until after their last PK sampling visit.  Subjects should 
also abstain from alcohol for 72 hours before the Screening Visit and their Follow-up 
Visit. 
4 
Subjects should abstain from caffeine-containing foods and beverages for 24 hours prior 
to first check-in (Day -1 of Treatment Period 1) until the Follow-up Visit. 
5 
Subjects should abstain from grapefruit or grapefruit juice, Seville oranges, quinine (e.g., 
tonic water) from 7 days prior to check-in (Day -1 of Treatment Period 1) until after their 
Follow-up Visit. 
6 
During admission periods, subjects will receive a standard diet, which excludes all 
alcohol and grapefruit-containing products.  No additional food or beverages must be 
consumed while in the Clinical Unit. 
7 
During the subjects’ outpatient periods, subjects should abstain from consuming, 
high-energy drinks (e.g., red bull), and food containing poppy seeds and any Over-the-
Counter (OTC) medication or herbal preparations until after their Follow-up Visit has 
been completed. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
40 of 94 
8 
Subjects will be required to abstain from blood or plasma donation until 3 months after 
the final medical examination at the study follow-up. 
For medication restrictions, refer to Section 9.7. 
7.2.1. 
Reproductive Restrictions 
7.2.1.1. 
Female Subjects 
A female subject who participates in the clinical trial must either: 
x 
Be of non-childbearing potential (surgically sterilized or postmenopausal as described in 
Section 7.2.1.1.1, OR 
x 
Of child-bearing potential and must be using highly effective methods of birth control as 
described in Section 7.2.1.1.2. 
7.2.1.1.1. 
Women of Non-Child Bearing Potential 
Women of non-childbearing potential are defined as female subjects who are permanently 
surgically sterilized or postmenopausal. 
Acceptable methods of sterilization include: 
x 
Surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks before 
Screening.  In the case of oophorectomy alone, only when the reproductive status of the 
woman has been confirmed by follow-up hormone level assessment. 
x 
Hysterectomy at least six weeks before Screening. 
x 
Bilateral salpingectomy. 
Females are considered postmenopausal if they have had amenorrhea for at least 12 months or 
more following cessation of all exogenous hormonal treatments and FSH levels are in the 
postmenopausal range (e.g., age appropriate, history of vasomotor symptoms) or for women 
< 60 years the FSH levels is > 40 mIU/mL.) 
7.2.1.1.2. 
Women of Child Bearing Potential 
Women of child bearing potential who are sexually active must agree to use, with their 
partner, an approved method of highly effective contraception from the time of verinurad 
administration until 3 months after the study Follow-up Visit. 
x 
A barrier method must be used in combination with one of the following methods, 
considered to be highly effective (failure rate < 1% per year when used consistently and 
correctly): 
o 
hormonal contraception, i.e., combined oral contraceptives, injectable1 or 
implantable1 hormonal contraceptives, 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
41 of 94 
o 
hormonal or non-hormonal intrauterine device1 (IUD, loop), established IUD1 or 
intrauterine system (Note: The IUD must have a failure rate < 1%), 
o 
Surgical sterilization1 (i.e., bilateral tubal ligation for females; vasectomy for 
male partners [must have been vasectomized before the female subject entered 
the clinical trial and he is the sole sexual partner of the female subject during the 
clinical trial,]) 
o 
observe abstinence (acceptable only if it is the subject’s usual lifestyle). 
x 
Barrier methods of contraception include: 
o 
Condom (without spermicidal foam/gel/film/cream/suppository or fat- or 
oil-containing lubricants), 
o 
Occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
gel/film/cream/suppository, 
x 
1 
These methods are considered to have low user dependency. 
Note: Double-barrier is not considered a highly effective method.  
Female subjects must agree not to attempt to become pregnant, must not donate ova and must 
not breastfeed starting at screening and throughout the clinical study and for 90 days 
(3 months) after the Follow-up Visit. 
Women should be informed of the potential risks associated with becoming pregnant while 
enrolled. 
Alternatively, * true abstinence is acceptable when it is in line with the subject’s preferred and 
usual lifestyle.  
*True abstinence: When this is in line with the preferred and usual lifestyle of the subject.  
(Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods], 
declaration of abstinence for the duration of a trial and withdrawal are not acceptable 
methods of contraception). 
Pregnancy Testing 
Women of child-bearing potential can be included only after a negative highly sensitive serum 
pregnancy test.  Additionally, urine pregnancy testing will be done as per the Schedule of 
Assessments (Table 5-2). 
7.2.1.2. 
Male Subjects 
Restrictions for male subjects 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
42 of 94 
Verinurad had no effects on fertility or embryo-foetal development in rats at doses up to 
300 mg/kg/day and did not affect embryo-foetal development in rabbits at doses up to 
30 mg/kg/day. 
Male subjects participating in this study are not required to apply contraception.  However, it 
is recommended that male subjects should not donate sperm until at least 3 months after the 
Follow-up Visit.  In addition, as a precaution, all male subjects should avoid fathering a child 
AND exposing a foetus to verinurad by either true abstinence or use together, with their 
female partner/spouse, of a highly effective method of contraception (see definition above), 
starting from the time of verinurad administration until at least 3 months after thee Follow-up 
Visit. 
Pregnancy 
Subjects will be instructed that if their partner becomes pregnant during the study this should 
be reported to the PI.  The PI should also be notified of pregnancy occurring during the study 
but confirmed after completion of the study.  In the event that a subject’s partner is 
subsequently found to be pregnant after the volunteer is included in the study, then consent 
will be sought from the partner and if granted any pregnancy will be followed and the status of 
mother and/or child will be reported to the Sponsor after delivery. 
A pregnancy notification form and follow-up will be completed. 
7.3. 
Replacement of Subjects 
Subjects who are withdrawn from the study due to AEs or changes in safety parameters will 
not be replaced unless a specific sample size is to be met for statistical purposes and if the 
Sponsor’s responsible physician and the PI agree it is safe to do so.  Subjects who withdraw or 
are withdrawn from the study for other reasons may be replaced following discussion with the 
Sponsor.  Subjects who were screened, but not randomised, may be rescreened as replacement 
subjects. 
Twenty-five (25) subjects will initially be randomised into the study in 5 treatment sequences 
(5 subjects per treatment sequence) to ensure at least 20 evaluable subjects (4 subjects per 
treatment sequence) at the end of the study.  Subjects will only be replaced if the subject 
number for evaluable subjects fall below 20 subjects or are less than 4 evaluable subjects per 
treatment sequence.  However, looking at previous studies and previous verinurad experience, 
at the current study design and dose level, it is highly unlikely to fall below these numbers, 
and replacements are unlikely to take place. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
43 of 94 
8. 
STUDY STOPPING RULES 
8.1. 
Discontinuation of Investigational Medicinal Product and 
Withdrawal from the Study 
Subjects must be discontinued from verinurad in the following situations:  
x 
Subject decision.  The subject is at any time free to discontinue treatment, without 
prejudice to further treatment.  
x 
Severe non-compliance to the Clinical Study Protocol (CSP). 
x 
Any significant and clinically relevant changes in the safety parameters (e.g., ECG, BP, 
pulse rate, laboratory assessments and AEs) making the continuation of verinurad 
administration unjustified. 
x 
Study specific withdrawal criteria: If a subject reports symptoms, which are considered 
unacceptable by the subject or the Investigator, he/she will be withdrawn from the study.  
In particular: 
 
Any other severe or SAE that is judged as possibly related to verinurad by the 
Investigator. 
 
Any case of Potential Hy’s Law according to Appendix 16.3. 
 
Study treatment will be stopped if a subject has elevated creatinine levels greater than 
1.5 times the pre-treatment value and retest of the creatinine will be performed as 
soon as possible (see Appendix 16.4). 
 
In subjects who report symptoms that indicate acute UA nephropathy including flank 
pain, nausea, or vomiting, treatment will be permanently discontinued.  Appendix 
16.4 contains guidelines on management of such subjects.  
 
See Appendix 16.4 for details on the handling of renal-related or urolithiasis 
treatment-emergent AEs, and the handling of serum creatinine elevation, which 
includes criteria for stopping treatment. 
 
Pregnancy. 
x 
The appropriate AE form in the case report form is to be completed. 
8.2. 
Premature Termination of the Study and Stopping Criteria 
The study will be put on temporary hold (defined as treatment stopped for enrolled subjects; 
and stop enrolment of subjects into the study) pending further safety data analysis if any of the 
following criteria occur in subjects receiving verinurad: 
x 
A “serious” adverse reaction (i.e., an SAE considered at least possibly related to 
verinurad administration as per guideline EMEA/CHMP/SWP/28367/07 Rev. 1) in 1 
subject; 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
44 of 94 
x 
“Severe” non-serious adverse reactions (i.e., severe non-serious AEs considered as, at 
least, possibly related to the IMP administration) in 2 subjects in the same treatment 
sequence, independent of within or not within the same System Organ Class (SOC). 
 
The study must be terminated prematurely if: 
x 
The PI and the Sponsor assess that the number and/or severity of AEs justify 
discontinuation of the study.  For instance, when there is at least 1 case of fatal SAE or 
2 cases of other SAEs, in both situations considered related to verinurad by the PI and the 
Sponsor. 
x 
The Sponsor considers the applied doses of the study drug to be no longer relevant. 
x 
The Sponsor decides to discontinue the study. 
x 
Data not known before it become available and raise concern about the safety of 
verinurad so that continuation would pose potential risks to the subjects. 
Premature termination of the study must be mutually agreed upon by the PI and the Sponsor 
and must be documented.  However, study results will be reported according to the 
requirements outlined in this CSP as far as applicable. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
45 of 94 
9. 
TREATMENTS 
9.1. 
Identity of the Investigational Medicinal Product 
Details on the identity of the investigational medicinal product (IMP) are presented in 
Table 9-1. 
Table 9-1 
Identity of the Investigational Medicinal Product 
Supplier: 
AstraZeneca 
Formulation: 
Verinurad ER8 capsule formulation 
Verinurad A-capsule formulation 
Verinurad B-capsule formulation 
Strength/concentration: 
12 mg: ER8 capsule formulation 
6 mg: A-capsule formulation 
6 mg B-capsule formulation 
Dose: 
12 mg 
Route of administration: 
Oral 
Regimen: 
Treatment 1: 1 x 12 mg verinurad ER8 capsule formulation, fasted. 
Treatment 2: 2 x 6 mg verinurad A-capsule formulation, fasted. 
Treatment 3: 2 x 6 mg verinurad A-capsule formulation, fed. 
Treatment 4: 2 x 6 mg verinurad B-capsule formulation, fasted. 
Treatment 5: 2 x 6 mg verinurad B-capsule formulation, fed. 
Special handling requirements: 
None. 
Details of the batch numbers will be included in the trial master file and the final CSR. 
9.2. 
Supply of Investigational Medicinal Product 
The IMP will be supplied by AstraZeneca and provided in bulk labelled with a study specific 
label and re-packaged into subject specific containers by PAREXEL, as applicable. 
A technical agreement between the PI and AstraZeneca will be in place to cover all pharmacy 
related activities, detailing roles and responsibilities prior to receipt of the IMPs at the Clinical 
Unit. 
A release document signed by a legally authorized Qualified Person (QP) at the Clinical Unit 
will be placed in the appropriate section of the Trial Master File to document labelling and 
dispensing of the study drug to the subject. 
9.3. 
Storage and Handling Procedures 
All IMPs will be stored in a secure facility, details of storage conditions will be provided on 
the label of the IMP. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
46 of 94 
The AstraZeneca will be permitted upon request to audit the supplies, storage, dispensing 
procedures and records provided that the blind of the study is not compromised. 
9.4. 
Labelling 
Labels will be prepared in accordance with Good Manufacturing Practice and local regulatory 
guidelines. 
The labels will fulfil Good Manufacturing Practices (GMP) Annex 13 requirements and 
medical device directive for labelling. 
9.5. 
Drug Accountability, Dispensing and Destruction 
Verinurad provided for this clinical study will be used only as directed in the CSP. 
In accordance with GCP, the Investigational Site will account for all supplies of verinurad.  
Details of receipt, storage, assembly/dispensing and return will be recorded. 
All unused supplies of verinurad will either be destroyed by PAREXEL or returned at the end 
of the study in accordance with instruction by the Sponsor. 
9.6. 
Dose and Treatment Regimens 
Subjects will receive single doses of different formulations of verinurad under fasted or fed 
conditions during the 5 treatment periods. 
For both the fasted and fed dosing, no fluids will be allowed apart from water which can be 
given until 1 hour prior and 1 hour after administration of verinurad, water to be given with 
the verinurad administration and the beverages provided with the high-fat, high-calorie 
breakfast in dosing periods with administration under fed conditions.  All subjects will be 
instructed to drink approximately 2 L to 2.5 L of liquid a day (including Day -1) throughout 
the duration of the study. 
All subjects will follow an overnight fast of at least 10 hours before the dosing procedures on 
Day 1: for the fed dosing, a high-fat, high-calorie standard breakfast will be provided 
30 minutes before the administration of verinurad, to be consumed in full at least 5 minutes 
before dosing; for the fasted dosing, no breakfast will be served, and subjects will remain 
fasted.  A meal can be given 4 hours after administration of verinurad for both dosing states. 
Following the restrictions above, each subject will receive a single-dose of different 
formulations of verinurad on each treatment period (5 occasions), respectively: 
Treatment 1 
Reference product 
ER8 capsule, fasted 
1 x 12 mg 
Treatment 2 
Test product 
A-capsule, fasted 
2 x 6 mg 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
47 of 94
Treatment 3
Test product
A-capsule, fed
2 x 6 mg
Treatment 4
Test product
B-capsule, fasted
2 x 6 mg
Treatment 5
Test product
B-capsule, fed
2 x 6 mg
Other restrictions are described in Section 7.2.
9.6.1.
FDA Breakfast Menu
The breakfast [19] will constitute the following:
x
2 eggs fried in butter,
x
2 strips of bacon,
x
2 slices of toast with butter,
x
120 g of fried potatoes,
x
240 mL of whole milk.
9.7.
Concomitant and Post-study Treatments
Apart from paracetamol/acetaminophen (if applicable) and hormone replacement therapy (if
applicable) and systemic contraceptives no concomitant medication or therapy will be 
allowed.
The subjects should be instructed that no other medication is allowed, including herbal 
remedies, vitamin supplements and OTC products, without the consent of the PI.
Medication, which is considered necessary for the subject’s safety and well-being, may be 
given at the discretion of the PI during the residential period.
When any medication is required, it should be prescribed by the PI.  Following consultation 
with the AstraZeneca Lead Physician, the PI should determine whether or not the subject 
should continue in the study.  Administration of concomitant medications that may influence 
the measurement of the PK and/or PD endpoints may be documented as a protocol deviation 
after consultation of the PI with the AstraZeneca Lead Physician.
9.8.
Treatment Compliance
Dosing will take place at the PAREXEL Early Phase Clinical Unit.
The administration of all IMPs will be recorded in
Compliance will be assured by direct supervision and witnessing of study drug administration.  
After IMP administration, a check of the subject’s mouth and hands will be performed.
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
48 of 94
9.9.
Randomization
9.9.1.
Subject Enrolment and Randomization
The PI will ensure:
x
Signed informed consent is obtained from each potential subject before any study specific 
procedures are performed.
x
Each potential subject is assigned a unique enrolment number at screening upon signing 
the Informed Consent.
x
The eligibility of each subject is in accordance with the inclusion and exclusion criteria.
x
Each eligible subject is assigned a unique randomization code.
Randomization to be done on Day -1 of Treatment Period 1.
Randomization codes will be assigned strictly sequentially as subjects become eligible for 
randomization (codes to be used without leading zero[s]).
When using unique enrolment number, the specific format must be followed (i.e., reduced 
enrolment number “01001” in 
 and on labels, full enrolment number “E0001001” 
for outputs).
If a subject withdraws his/her participation in the study, then his/her enrolment/randomization 
code cannot be re-used.  If a replacement is mandated, replacement subjects will receive a new 
randomization number and will be allocated to 
9.9.2.
Procedures for Randomization
Upon completion of the randomization requirements specifications form, the randomization 
will be produced by PAREXEL according to the AstraZeneca randomization system 
(AZRand).
Subjects will be randomised to treatment sequences in a ratio of 1:1:1:1:1 so that all subjects 
will receive all formulations of verinurad.  The reference capsules (Treatment 1) will be given 
under fasted conditions, while the new formulations (Treatments 2, 3, 4 and 5) will be given 
under both fasted or fed conditions as per study design (see Section 5.3.2).
The randomization will be completed using consecutive randomization codes.
The number of subject identifiers generated for the study will account for the number of 
randomised subjects per the sample size calculation (N = 20 [see Section 12.4]) as well as 
providing sufficient randomization numbers for replacements.  For this study, a total of 
CCI
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
49 of 94 
25 subject identifiers will be randomly assigned to the 5 treatment sequences: 12345, 23451, 
51234, 34512 and 45123. 
9.9.3. 
Procedures for Handling Incorrectly Randomised Subjects 
Subjects who fail to meet the inclusion criteria or meet any exclusion criterion should not, 
under any circumstances, be randomised into the study.  There can be no exceptions to this 
rule. 
Where a subject, who does not meet the selection criteria, is randomised in error and this is 
identified before dosing, the subject should be withdrawn from the study.  If a subject is 
withdrawn prior to dosing they will be replaced. 
If a subject, who does not meet the selection criteria, has been dosed before the error is 
identified, the subject should be withdrawn and advised to continue safety assessments to 
ensure their safety.  The PI will inform the AstraZeneca Lead Physician of the error and a 
joint decision made as to whether the subject should be replaced. 
9.10. 
Blinding 
This is an open-label study. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
50 of 94 
10. 
MEASUREMENTS AND METHODS OF ASSESSMENTS 
10.1. 
Appropriateness of Measurements 
Standard measures to assess PK, safety and tolerability apply during the study.  For the single 
doses of verinurad planned to be given during this study, no safety issues are expected. 
For timing of assessments refer to Table 5-2. 
10.2. 
Pharmacokinetics 
10.2.1. 
Sample Collection and Handling 
Blood samples for the determination of plasma concentrations of verinurad will be collected 
for each treatment period as specified in the Schedule of Assessments (Table 5-2). 
Samples will be collected, handled, labelled, stored and shipped as detailed in the Laboratory 
Manual. 
10.2.2. 
Pharmacokinetic Drug Assays 
Blood samples for determination of verinurad concentrations in plasma will be analysed by 
Covance Bioanalytical Services on behalf of AstraZeneca, using a validated assay.  Additional 
analyses may be conducted on the biological samples to further investigate the presence 
and/or identity of drug metabolites. 
Full details of the analytical method and analyses performed will be described in a separate 
Bioanalytical Report. 
10.3. 
Safety and Eligibility Measurements 
Safety and tolerability variables will include: 
x 
Adverse events 
x 
Vital signs (systolic and diastolic BP, pulse rate) 
x 
ECG 
x 
Physical examination 
x 
Laboratory assessments (haematology, clinical chemistry and urinalysis). 
 
Viral serology and drugs of abuse, alcohol and cotinine will be assessed for eligibility.  
Follicle Stimulation Hormone (females only), pregnancy testing (females only) and use of 
concomitant medication will also be assessed and reported. 
10.3.1. 
Adverse Events 
Refer to Section 13.2.3. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
51 of 94
10.3.2.
Vital Signs
The following variables will be collected after the subject has rested in the supine position for 
at least 5 minutes:
x
Systolic BP (mmHg)
x
Diastolic BP (mmHg)
x
Pulse rate (beats per minute [bpm])
The measurement of vital signs will be carried out according to the relevant PAREXEL 
standard operating procedures (SOPs).
10.3.3.
Electrocardiograms
Resting 12-lead Electrocardiogram
At the time points specified in the Schedule of Assessments (Table 5-2), a 10-second 12-lead 
safety ECG will be obtained after 10 minutes supine rest) using the sites own ECG machines.
The PI and/or deputy PI will judge the overall interpretation as normal or abnormal and this 
evaluation will be reported in 
.  If abnormal, it will be further documented as to 
whether or not the abnormality is clinically significant by the PI.  For all abnormalities 
(regardless of clinical significance) the specific type and nature of the abnormality will be 
documented in 
  Clinically significant findings should also be documented on the 
AE page of the CRF if applicable.
The PI may add extra 12-lead resting ECG safety assessments if there are any abnormal 
findings or if the PI considers it is required for any other safety reason.  These assessments 
should be entered as an unscheduled assessment.
All ECG readings will be digitally stored as source documents.
10.3.4.
Physical Examination
Full
The complete physical examinations will include an assessment of the general appearance, 
respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and 
throat), lymph nodes, thyroid, musculoskeletal and neurological systems.
Brief (Abbreviated)
The brief physical examinations will include an assessment of the general appearance, skin, 
abdomen, cardiovascular system and respiratory.
CCI
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
52 of 94 
10.3.5. 
Laboratory Assessments 
10.3.5.1. 
Haematology 
Haematology  
White blood cell count 
Neutrophils absolute count  
Red blood cell count 
Lymphocytes absolute count  
Haemoglobin 
Monocytes absolute count  
Haematocrit 
Eosinophils absolute count  
Mean corpuscular volume 
Basophils absolute count  
Mean corpuscular haemoglobin 
Platelets 
Mean corpuscular haemoglobin concentration 
Reticulocytes absolute count  
 
10.3.5.2. 
Serum Clinical Chemistry 
Serum Clinical Chemistry 
Sodium 
Alkaline phosphatase 
Potassium 
ALT 
BUN 
AST 
Creatinine 
GGT 
Albumin 
Total Bilirubin 
Calcium 
Unconjugated bilirubin 
Phosphate 
Serum uric acid 
Glucose(fasting) 
 
C-reactive protein 
 
FSH 
 
 
10.3.5.3. 
Urinalysis 
Urinalysis 1 
 
Glucose 
 
Protein 
 
Blood 
 
1 
Upon a positive urine test from leucocytes, blood, nitrite or protein, the Investigator may require further 
urine analysis, such as flow cytometry.  Results of additional urine analyses will be included in the database.  If 
the flow cytometry examination shows a different result than the urine sticks, the urine will be investigated by 
fully automated digital imaging where leukocytes, erythrocytes, casts in urine will be analysed. 
10.3.5.4. 
Pregnancy Testing 
Pregnancy test (females only) 
Human-beta chorionic gonadotrophin (Blood) 
Urine assessment 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
53 of 94 
 
10.3.5.5. 
Viral Serology 
Viral Serology 
Human immunodeficiency virus (HIV) I and II 
Hepatitis C Virus antibody 
Hepatitis B surface antigen (HBsAg) 
anti-HBc antibody 
 
10.3.5.6. 
Drugs of Abuse, Alcohol and Cotinine 
Drugs of Abuse and Alcohol 
Amphetamine / Ecstasy 
Benzodiazepines 
Ethanol 
Methadone Metabolites 
Cannabinoids 
Barbiturates 
Cocaine 
Phencyclidine 
Opiates  
Urine Creatinine 
Cotinine 
 
Tricyclic anti-depressants 
 
 
10.3.6. 
Concomitant Medication 
Refer to Section 9.7. 
10.4. 
Procedures for Handling of Biological Samples 
10.4.1. 
Storage and Destruction of Biological Samples 
Samples will be disposed of, on instruction from AstraZeneca, after the CSR has been 
finalized, unless samples are retained for additional or future analyses. 
10.4.1.1. 
Pharmacokinetic Samples 
Pharmacokinetic samples will be disposed of after the Bioanalytical Report finalization or 
6 months after issuance of the draft Bioanalytical Report (whichever is earlier), unless 
requested for future analyses. 
Pharmacokinetic samples may be disposed of or anonymized by pooling.  Additional analyses 
may be conducted on the anonymized, pooled PK samples to further evaluate and validate the 
analytical method.  Any results from such analyses may be reported separately from the CSR. 
Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis 
of the test samples.  The results from the evaluation will not be reported in the CSR but 
separately in a Bioanalytical Report. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
54 of 94 
Samples will be collected, handled, labelled, stored and shipped as detailed in the Laboratory 
Manual. 
10.4.2. 
Labelling and Shipment of Biohazard Samples 
Samples will be labelled and shipped in accordance with the Laboratory Manual and the 
Biological Substance, Category B regulations (materials containing or suspected to contain 
infectious substances that do not meet Category A criteria) (for International Airline 
Transportation Association [IATA] guidance, see Appendix 16.2 of this CSP). 
Any samples identified as Infectious Category A materials will not be shipped and no further 
samples will be taken from the subject unless agreed with AstraZeneca and appropriate 
labelling, shipment and containment provisions are approved. 
10.4.3. 
Chain of Custody of Biological Samples 
A full chain of custody will be maintained for all samples throughout their lifecycle. 
The PI will ensure full traceability of collected biological samples from the subjects while in 
storage at the centre until shipment and will keep documentation of receipt of arrival. 
The sample receiver will keep full traceability of samples while in storage and during use, 
until used, disposed of, or until further shipment or disposal (where appropriate) and will keep 
documentation of receipt of arrival. 
10.4.4. 
Withdrawal of Informed Consent for Donated Biological Samples 
If a subject withdraws consent to the use of donated biological samples, the samples will be 
disposed if not already analysed and the action documented. 
As collection of donated biological samples is an integral part of the study then the subject is 
withdrawn from further study participation. 
AstraZeneca ensures the central laboratory(ies) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroyed, the action 
documented, and the signed document returned to the Clinical Unit. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
55 of 94
11.
DATA QUALITY ASSURANCE AND DATA MANAGEMENT
11.1.
Quality Control and Source Data Verification
Source data verification will be conducted with due regard to subject confidentiality.
The Clinical Unit will allow the study monitor and Sponsor representative direct access to all 
study documents, medical files and source documents to enable verification of the study data, 
while maintaining the anonymity of the subject and confidentiality of the data.
Internal quality control will be performed at all stages of the study by the Clinical Unit.
11.2.
Audit/Inspections
The Clinical Unit facilities and all study data/documentation may be audited/inspected by 
independent auditor/inspector/any representatives of regulatory authorities.  The PI must allow 
the applicable persons access to all relevant facilities and data/documents.  The PI must be 
available to discuss any findings/issues.
If an audit was performed, the audit certificate will be included in the CSR.
11.3.
Study Monitoring
The conduct of the study will be monitored by an independent PAREXEL monitor or a 
subcontracted monitor to ensure compliance with applicable regulatory requirements and 
GCP.  The summary of the documentation of the monitoring visits will form part of the study 
documentation and will be archived as such.
11.4.
Data Collection
The 
 system is an electronic source data capturing and information management 
system.  The system combines all aspects of source data capturing with process control and 
clinical study management.  All clinical and laboratory data, except those which are 
paper-based or provided by an external vendor, will be collected in 
  Only paper-
based data will be subject to data entry.  For electronic source data, no data entry will be 
performed.
The responsible study monitor will check data at the monitoring visits to the Clinical Unit.  
The PI will ensure that the data collected are accurate, complete and legible.  Data will be 
monitored within 
 by the study monitor before being exported.  Any changes made 
during monitoring will be documented with a full audit trail within 
.
CCI
CCI
CCI
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
56 of 94
11.4.1.
Case Report Forms and Source Documents
All data obtained using paper collection methods during the clinical study will be recorded in 
  All source documents from which 
 entries are derived should be 
placed in the subject’s personal records.
The original
 entries for each subject will be checked against source documents by 
the study monitor.  Instances of missing or uninterpretable data will be discussed with the PI 
for resolution.
11.4.2.
Access to Source Documents
During the course of the clinical study, a study monitor will make Clinical Unit visits to 
review protocol compliance, compare 
 entries and individual subject’s personal 
records, assess IMP accountability and ensure that the clinical study is being conducted 
according to pertinent regulatory requirements.
 entries will be verified against 
source documents.  The review of medical records will be handled confidentially to ensure 
subject anonymity.
Checking of the 
 entries for completeness and clarity and verifying with source 
documents, will be required to monitor the clinical study for compliance with GCP and other 
regulations.  Moreover, regulatory authorities of certain countries, IECs/IRBs may wish to 
carry out source data inspections on-site, and the Sponsor’s clinical quality assurance group 
may wish to carry out audits.  Direct access to source data will be required for these 
inspections and audits; they will be carried out giving due consideration to data protection and 
subject confidentiality.  The PI assures the Sponsor of the necessary support at all times.
11.5.
Data Management
PAREXEL will utilize standardized and validated procedures and systems to collect, process 
and file the clinical data of this study.  Any system used will be compliant with FDA 21 CFR 
Part 11 requirements.
A data management plan (DMP) will be prepared to describe the processes and data-flow 
within the clinical study.  Timelines, versions for the computer systems and the coding will be 
defined in the DMP, and if applicable, Sponsor specific requests will also be documented 
within.  The DMP will be finalized before the first dose where possible but before database 
lock.
A data validation specification (DVS) will be created to outline the validation checks to be 
performed during the study.  The DVS must be finalized before data validation.
After the data has been monitored by the responsible study monitor all data received will be 
reviewed, logged and filed.
CCI
CCI
CCI
CCI
CCI
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
57 of 94 
The raw data intended for further processing will be checked by standard routines or 
according to the DVS and queries will be generated and sent to the PI for review and 
resolution.  Corrections resulting from these queries will be confirmed on the data clarification 
forms.  This process will be repeated until no further discrepancies are found.  The data will 
then be declared as clean.  Applicable documentation will be stored in the study files. 
Only trained study staff will have access to the clinical database and every change in data will 
have a full audit trail. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
58 of 94
12.
STATISTICAL METHODS
12.1.
Overview
The statistical methodology below describes the statistical analysis as it is foreseen when the 
study is being planned.
If circumstances should arise during the study rendering the analysis inappropriate, or if in the 
meantime improved methods of analysis should come to light, different analyses may be 
performed.  A separate statistical analysis plan (SAP) will not be written for the study.  Any 
deviations from the statistical methodology defined in this protocol, reasons for such 
deviations and all alternative/additional statistical analyses that may be performed will be 
described in the CSR.  Such changes to analyses may be written into an abbreviated SAP, if 
appropriate.  The verification and review of all statistical modelling assumptions will be 
documented appropriately.
12.2.
General Statistical Methodology
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
59 of 94
All statistical analyses and production of tables, figures and listings will be performed using 
SAS® version 9.4 or later.
12.2.1.
Missing Data
Missing dates and times in the AE data will be handled as described in Section 12.10.1.
Concentrations that are non-quantifiable (NQ) in the PK data will be handled as described in 
Section 12.9.2.
There will be no imputations of other missing data.  All randomised and dosed subjects will be 
included into the safety analyses as far as the data permit.
12.3.
Study Populations
12.3.1.
Safety Analysis Set
The safety analysis set will include all subjects who received at least 1 dose of verinurad (any 
formulation) and for whom any safety post-dose data are available.
Unless otherwise stated, the safety analysis set will be used for the presentation of all
demographic and disposition data, as well as all safety analyses.  Exposure to IMP will also be 
presented using the safety analysis set.
12.3.2.
Pharmacokinetic Analysis Set
The PK analysis set will consist of all subjects in the safety analysis set for whom at least 1 of
the primary PK parameters can be calculated, and who have no major protocol deviations 
thought to impact on the analysis of the PK data. All the eligible PK data will be presented 
for each treatment using descriptive statistics. For the formal relative bioavailability 
evaluations, only subjects who provide eligible PK data for both Test and Reference 
treatments can be included for each comparison.
Pharmacokinetic data for a subject during any treatment period may be excluded from the 
corresponding descriptive and formal statistics as a result of the following:
x
an AE of vomiting occurring at or before median tmax for that treatment,
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
60 of 94
x
a pre-dose concentration of verinurad > 5% of Cmax for that treatment.
If either of these occur for any subject during all treatment periods then the subject will be 
excluded from the PK analysis set.
Individual PK concentration data may be excluded from the PK analysis and/or statistical 
analyses and corresponding figures.  The exclusion of any subjects from the PK analysis set, 
of any individual concentration-time points from the calculation of the PK parameters or from 
the statistical analyses and corresponding figures and of any individual PK parameters from 
the statistical analyses and corresponding figures will be documented by the PK Scientist 
including the reasons for exclusion.
All available reportable concentration data and PK parameter data will be listed.  
Concentration or parameter data for subjects excluded from the statistical summaries or 
formal statistics will be presented in the corresponding individual concentration versus time or 
PK parameter figures but not in the corresponding summary figures.
12.4.
Determination of Sample Size
12.5.
Protocol Deviations
Per Protocol set will be based on protocol deviations and it is defined as all subjects included 
in the safety analysis set with no major protocol deviations.
Protocol deviations are considered any deviation from the clinical study protocol relating to a 
subject, and include the following:
x
Inclusion/exclusion criteria deviations.
x
Dosing deviations (e.g., incorrect treatment received, subject was not fasted as per the
protocol requirements prior to and after dosing).
x
Time window deviations for safety and/or PK assessments.
x
Subjects receiving prohibited concomitant medications.
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
61 of 94 
x 
Other procedural and study conduct deviations recorded by the Clinical Unit on a protocol 
deviation log. 
 
The criteria for the assessment and reporting of protocol deviations will be stipulated in a 
separate study specific protocol deviation specification document.  This will include a 
Windows Allowance Document which stipulates tolerance windows for safety and PK 
assessments.  Measurements performed within these tolerance windows will not be considered 
as protocol deviations and will not be reported. 
Pharmacokinetic samples where the actual time of collection deviates by more than 10% from 
the protocol scheduled collection time will be included in the PK analysis to determine the PK 
parameters but will be excluded from the summary statistics and corresponding plots. 
All protocol deviations will be discussed at the data review meeting prior to database hard 
lock in order to define the analysis sets for the study. 
Important protocol deviations will be listed by subject. 
Protocol deviations will be handled in accordance with PAREXEL SOPs. 
For handling of protocol amendments, see Section 3.6. 
12.6. 
Subject Disposition 
A randomization listing will be presented and include the following: each subject’s 
randomization number, the subject’s full enrolment number, the treatment sequence to which 
the subject has been randomised and the country where the study centre is located. 
Subjects and/or data excluded from the PK analysis set will be listed including the reason for 
exclusion.  Subject disposition will be summarized and will include the following information: 
number of subjects randomised and dosed, number and percentage of subjects completing the 
study and the number and percentage of subjects who were withdrawn (including reasons for 
withdrawal).  Disposition data will be presented based on all subjects randomised (subjects 
entered into the study that received a randomization number, prior to dosing). 
Subject discontinuations will be listed including the date of study exit, duration of treatment 
and reason for discontinuation.  A listing of informed consent response will also be presented. 
12.7. 
Demographic and Baseline Data 
Demographic variables (age, gender, race, ethnicity, height, weight and BMI) will be listed by 
subject.  Demographic characteristics (age, gender, race and ethnicity) and subject 
characteristics (height, weight and BMI) will be summarized separately by treatment sequence 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
62 of 94
and overall for all randomised subjects.  The denominator for percentages will be the number 
of randomised subjects.
Medical history data will be listed by subject including visit, description of the 
disease/procedure, Medical Dictionary for Regulatory Activities (MedDRA) System Organ 
Class (SOC), MedDRA Preferred Term, start date and stop date (or ongoing if applicable).
12.8.
Prior and Concomitant Medication and Drug Administration
12.8.1.
Prior and Concomitant Medication
Prior medications are those that started and stopped prior to the first dose of IMP; all 
medications taken after first dosing are considered as concomitant (including medications that 
started prior to dosing and continued after).  Prior medication started within 3 months prior to 
the first dose of IMP will be recorded also in the concomitant medication module of 
Prior and concomitant medication will be listed by subject and will include the following 
information: reported name, preferred term, the route of administration, dose, frequency, start 
date/time, duration and indication. Prior and concomitant medication will be coded according 
to the Sponsor’s drug dictionary.
12.8.2.
Drug Administration
Drug administration dates and times will be listed for each subject and treatment period.  
Details of high-fast, high-calorie breakfast will be listed.
12.9.
Pharmacokinetic Analysis
12.9.1.
Pharmacokinetic Parameters
Where possible, the following PK parameters will be determined for verinurad using plasma 
concentrations.
Primary PK parameters
AUC
Area under plasma concentration-time curve from time zero to infinity
AUC0-t
Area under the plasma concentration-time curve from time zero to time of last 
quantifiable concentration
Cmax
Maximum observed plasma concentration
Secondary PK parameters
AUC0-24
Area under the plasma concentration-time curve from time zero to 24 hours
tmax
Time to reach maximum observed plasma concentration
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
63 of 94 
t½λz 
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-
time curve 
CL/F 
Apparent total body clearance of drug from plasma after extravascular 
administration (parent drug only) 
MRT 
Mean residence time of the unchanged drug in the systemic circulation from zero 
to infinity 
tlast 
Time to reach last quantifiable plasma concentration 
Vss/F 
Apparent volume of distribution during the terminal phase after extravascular 
administration (parent drug only) 
Vz/F 
Apparent volume of distribution during the terminal phase after extravascular 
administration 
 
The following diagnostic parameters for plasma PK analysis will be listed, but not 
summarized: 
t lower 
Start of exponential fit 
t upper 
End of exponential fit 
λzN 
Number of data points included in the log-linear regression analysis 
Rsq_adj 
Regression coefficient adjusted for the λzN, Goodness-of-fit statistic for 
calculation of λz 
%AUCextr 
Percentage of AUC obtained by extrapolating the area under the plasma 
concentration-time curve from the time of the last quantifiable concentration to 
infinity 
λz 
Terminal elimination rate constant 
 
Additional PK parameters may be determined where appropriate. 
12.9.2. 
Derivation of Pharmacokinetic Parameters 
The PK analyses of the plasma concentration data for verinurad will be performed by Covance 
Clinical Pharmacokinetic Alliance on behalf of AstraZeneca R&D. 
PK parameters will be derived using non-compartmental methods with Phoenix® WinNonlin® 
Version 8.1, or higher.  All descriptive and inferential statistical computations will be 
performed using SAS® Version 9.4, or higher. 
PK analysis will, where possible, be carried out using actual times recorded in the raw data.  If 
actual times are missing, nominal times will be used. 
Plasma concentrations which are NQ prior to the first quantifiable concentration will be set to 
a value of zero.  After the first quantifiable concentration, any NQ plasma concentrations will 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
64 of 94 
be set to missing for all concentration profiles.  Where 2 or more consecutive concentrations 
are NQ at the end of a profile, the profile will be deemed to have terminated and therefore any 
further quantifiable concentrations will be set to missing for the calculation of the PK 
parameters unless it is considered to be a true characteristic of the profile of the drug. 
If an entire concentration-time profile is NQ, the profile will be excluded from the PK 
analysis. 
Cmax, tmax and tlast will be taken directly from the plasma concentration-time profile. 
Terminal elimination half-life, calculated as (ln2)/λz, will be estimated by log-linear least 
squares regression of the terminal part of the concentration-time curve.  For the determination 
of λz, the start of the terminal elimination phase for each subject will be defined by visual 
inspection and will be the first point at which there is no systematic deviation from the 
log-linear decline in plasma concentrations (t lower).  The last point (t upper) will be the time of 
the last quantifiable plasma concentration.  A minimum of 3 data points will be used in 
calculating λz, and the duration of time over which λz is recommended to be at least 3 times 
the subsequently estimated terminal half-life.  Where an elimination half-life is estimated over 
less than 3 times the subsequently estimated terminal half-life, it will be flagged and 
commented upon in the study report by agreement with the Sponsor. 
The Rsq_adj value will be calculated to show the goodness-of-fit of the log-linear regression 
taking into consideration the number of points used in the estimation.  To achieve a good 
precision in the estimation, the Rsq_adj value should be high, a value of ≥ 0.8 being indicative 
of good correlation.  Any λz with a Rsq_adj of < 0.8 will be flagged in the data listings along 
with any parameters derived from λz (e.g., t½λz, AUC, CL/F, Vz/F and %AUCextr) and 
agreement reached with the Sponsor regarding any exclusion of data from the summaries. 
AUC values, including AUC and AUC0-t, will be calculated using the linear trapezoidal 
method when concentrations are increasing and the logarithmic trapezoidal method when 
concentrations are decreasing (linear up, log down method).  AUC is estimated by AUC0-t + 
Clast/λz where Clast is the observed last quantifiable drug concentration.  The AUC values 
where the percentage extrapolation is greater than 20% and any parameters dependent on 
AUC will be flagged in the data listings and agreement reached with the Sponsor on whether 
exclusions from the summary or formal statistics are required. 
The minimum requirement for the calculation of AUC will be the inclusion of at least 
3 consecutive plasma concentrations above the lower limit of quantification (LLOQ), with at 
least 1 of these concentrations following Cmax. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
65 of 94 
Apparent clearance (CL/F) will be determined from the ratio of dose/AUC.  Apparent volume 
of distribution based on the terminal phase (Vz/F) will be determined from the ratio of 
dose/λz*AUC.  Vss/F will be determined by multiplying CL/F by MRT. 
12.9.3. 
Presentation of Pharmacokinetic Data 
A listing of PK blood sample collection times, as well as derived sampling time deviations 
will be provided.  Plasma concentrations will be summarized for the PK analysis set for each 
time point by treatment using the following descriptive statistics: n, n below LLOQ, geometric 
mean (gmean), geometric coefficient of variation [CV] (gCV%), arithmetic mean, arithmetic 
SD, gmean ± geometric SD (gSD) (gmean + gSD and gmean - gSD), median, minimum (min) 
and maximum (max). 
The gmean is calculated as the exponential(μ) where μ is the arithmetic mean calculated using 
log-transformed data. 
The gCV% is calculated as 100*sqrt[exp(s2)-1] where s is the SD of the log-transformed data.  
The gmean ± gSD (gmean - gSD and gmean + gSD) are calculated as exp[μ ± s].  
Pharmacokinetic concentration data will be presented in the listings to the same number of 
significant figures as the data received from the bioanalytical laboratory (usually to 
3 significant figures) and against the same units as received.  Pharmacokinetic concentration 
descriptive statistics will all be presented to 4 significant figures with the exception of the min 
and max which will be presented to 3 significant figures and n and n < LLOQ which will be 
presented as integers.  
Individual concentrations with time deviations of greater than ± 10% from the protocol 
scheduled time will be used in the PK analysis but will be flagged for exclusion from the 
summary tables and corresponding figures.  
Plasma concentrations that are NQ, Not Reportable or missing will be handled as follows:  
Individual concentrations below the LLOQ of the bioanalytical assay will be reported as NQ 
in the listings with the LLOQ defined in the footnotes of the relevant tables, figures and 
listings. Individual plasma concentrations that are Not Reportable will be reported as no result 
(NR) and those that are missing will be reported as NS (No Sample) in the listings.  Plasma 
concentrations that are NQ, NR or NS will be handled as follows for the provision of 
descriptive statistics:  
x 
Any values reported as NR or NS will be excluded from the summary tables and 
corresponding figures. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
66 of 94 
x 
At a time point where less than or equal to 50% of the concentration values are NQ, all 
NQ values will be set to the LLOQ, and all descriptive statistics will be calculated 
accordingly. 
x 
At a time point where more than half of the values are NQ, the gmean, gmean + gSD, 
gmean-gSD and gCV% will be set to not calculable (NC).  The maximum value will be 
reported from the individual data, and the minimum and median will be set to NQ. 
x 
If all values are NQ at a time point, no descriptive statistics will be calculated for that 
time-point.  The gmean, minimum, median and maximum will be reported as NQ and the 
gCV% and gmean ± gSD as NC. 
x 
The number of values below LLOQ (n < LLOQ) will be reported for each time-point 
together with the total number of collected values (n). 
Three observations > LLOQ are required as a minimum for a plasma concentration to be 
summarized.  Two values > LLOQ are presented as a minimum and maximum with the other 
summary statistics as NC.  
All reportable plasma PK parameters will be listed for each subject and treatment.  A separate 
listing will be provided for the diagnostic PK parameters. 
Plasma PK parameters will be summarized for the PK analysis set by treatment using the 
following descriptive statistics: 
x 
Cmax, AUC, AUC(0-t), and AUC(0-24): present n, gmean, gmean + gSD, gmean-gSD, 
arithmetic mean, arithmetic SD, gCV(%), median, min and max. 
x 
t½λz, CL/F, Vz/F, Vss/F and MRT: present n, gmean, gmean + gSD, gmean-gSD, 
arithmetic mean, arithmetic SD, gCV(%), median, min and max. 
x 
tmax and tlast present n, median, min and max. 
x 
Diagnostic parameters (e.g., λz, t upper, t lower, λzN, Rsq_adj and %AUCextr): listed 
only and not summarized. 
Three values are required as a minimum for PK parameters to be summarized.  Two values are 
presented as a min and max with the other summary statistics as NC. 
If one or more values for a given parameter is zero (or imputed with zero), then no geometric 
statistics will be calculated for that parameter and the results for geometric statistics will be set 
to NA (not applicable). 
Pharmacokinetic parameter listings will be presented according to the following rules: 
x 
Cmax – present to the same number of significant figures as received from the 
bioanalytical laboratory. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
67 of 94 
x 
tmax, tlast, t lower and t upper – present as received in the data, usually to 2 decimal 
places. 
x 
AUC, AUC(0-t), AUC(0-24), t½λz, CL/F, Vz/F, Vss/F, MRT, Cmax, λz, %AUCextr, 
Rsq_adj will be presented to 3 significant figures. 
x 
λzN – will be presented as an integer (no decimals).  
The descriptive statistics for PK parameter data will all be presented to 4 significant figures 
with the exception of the min and max which will be presented to 3 significant figures apart 
from the following:  
x 
tmax and tlast: –present as received in the data, usually to 2 decimal places. 
Pharmacokinetic data (concentrations and parameters) from subjects excluded from the PK 
analysis set will be included in the data listings, but not in the descriptive statistics or in the 
inferential statistics as appropriate. 
Individual subject plasma concentrations versus actual time will be plotted in linear and 
semi-logarithmic scale with all treatments overlaid on the same plot and separate plots for 
each subject. 
Combined individual subject plasma concentration versus actual times will be plotted in linear 
and semi-logarithmic scale.  Separate plots will be presented for each treatment. 
Geometric mean plasma concentration (±gSD) versus nominal sampling time will be plotted 
in linear and semi-logarithmic (no SD presented) scale with separate plots for all treatments 
on the same figure and with the fasted and fed treatments on the same figure for each study 
formulation. 
All gmean plots or combined plots showing all subjects by treatment will be based on the PK 
analysis set.  Individual plots by subject will be based on the safety analysis set. 
For consistency, the plasma concentration values used in the gmean data graphs will be those 
given in the descriptive statistics summary table for each time-point. 
For gmean concentration-time plots, NQ values will be handled as described for the 
descriptive statistics; if the geometric mean is NQ, the value plotted will be zero for linear 
plots and missing for semi-logarithmic plots.  Any gmean ± gSD error bar values that are 
negative will be truncated at zero on linear concentration-time plots and omitted from semi-
logarithmic plots. 
For individual plots, plasma concentrations which are NQ prior to the first quantifiable 
concentration will be set to a value of zero (linear plots only).  After the first quantifiable 
concentration, any NQ plasma concentrations will be regarded as missing. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
68 of 94 
12.9.4. 
Statistical Analysis of Pharmacokinetic Data 
For each individual relative bioavailability comparison the ratios of Cmax, AUC0-t and AUC 
will be calculated for Test:Reference  using log transformed data. 
The following comparisons of relative bioavailability (AUC, AUC0-t and Cmax) of verinurad 
will be performed: 
x 
Treatment 2 versus 1 i.e., “A capsule, fasted” versus “ER8 capsule, fasted” 
x 
Treatment 4 versus 1 i.e., “B capsule, fasted” versus “ER8 capsule, fasted” 
x 
Treatment 3 versus 1 i.e., “A capsule, fed” versus “ER8 capsule, fasted” 
x 
Treatment 5 versus 1 i.e., “B capsule, fed” versus “ER8 capsule, fasted” 
x 
Treatment 4 versus 2 i.e., “B capsule, fasted” versus “A capsule, fasted” 
x 
Treatment 5 versus 3 i.e., “B capsule, fed” versus “A capsule, fed” 
x 
Treatment 3 versus 2 i.e., “A capsule, fed” versus “A capsule, fasted” 
x 
Treatment 5 versus 4 i.e., “B capsule, fed” versus “B capsule, fasted” 
Analyses will be performed using a linear fixed-effects analysis of variance model using the 
natural logarithm of AUC, AUC0-t and Cmax as the response variables, sequence, period and 
treatment as fixed effects, volunteer nested within sequence as a random effect.  Transformed 
back from the logarithmic scale, geometric means together with confidence intervals (CIs) 
(2-sided 95%) for AUC, AUC0-t and Cmax will be estimated and presented.  Also, ratios of 
geometric means together with CIs (2-sided 90%) will be estimated and presented. 
12.10. 
Analysis of Safety Data 
Safety data (scheduled and unscheduled) will be presented in the data listings.  Continuous 
variables will be summarized using descriptive statistics (n, mean, SD, minimum, median, 
maximum) by treatment.  Categorical variables will be summarized in frequency tables 
(frequency and proportion) by treatment.  The analysis of the safety variables will be based on 
the safety analysis set. 
Adverse events will be summarized by Preferred Term and SOC using MedDRA vocabulary.  
Furthermore, listings of SAEs and AEs that led to withdrawal of the IMP and/or from the 
study will be made and the number of subjects who had any AE, SAEs, AEs that led to the 
withdrawal, and AEs with severe intensity will be summarized.  Adverse events that occur 
before dosing will be reported separately. 
Tabulations and listings of data for vital signs, clinical laboratory tests and ECGs will be 
presented.  Any new or aggravated clinically relevant abnormal medical physical examination 
finding compared to the baseline assessment will be reported as an AE.  Data will be 
summarized for the observed values at each scheduled assessment, together with the 
corresponding changes (and/or percentage change) from the baseline when baseline is defined.  

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
69 of 94 
Clinical laboratory data will be reported in the units provided by the clinical laboratory for the 
Safety Review Committee meeting, and in Système International units in the CSR. 
Out-of-range values for safety laboratory, vital signs and ECGs will be flagged in individual 
listings as well as summarized descriptively using agreed standard reference ranges and/or 
extended reference ranges (e.g., AZ, program, or laboratory ranges). 
12.10.1. 
Adverse Events 
All AEs will be coded using MedDRA vocabulary and will be listed for each subject.  A 
treatment-emergent adverse event is defined as an AE with onset (start date/time) after the 
first dose of verinurad in Treatment Period 1. 
Adverse events will be assigned to a treatment based on the start date/time of the AE in 
relation to dosing in that period; for tabulation purposes the AE will then be assigned to the 
treatment received in the respective treatment period as follows: 
x 
Screening: all SAEs with start date/time prior to dosing in Treatment Period 1. 
x 
Treatment Period 1: AEs with start date/time at the time of or after dosing in Treatment 
Period 1 until the time of dosing in Treatment Period 2. 
x 
Treatment Period 2: AEs with start date/time at the time of or after dosing in Treatment 
Period 2 until the time of dosing in Treatment period 3. 
x 
Treatment Period 3: AEs with start date/time at the time of or after dosing in Treatment 
Period 3 until the time of dosing in Treatment Period 4. 
x 
Treatment Period 4: AEs with start date/time at the time of or after dosing in Treatment 
Period 4 until the time of dosing in Treatment Period 5. 
x 
Treatment Period 5: AEs with start date/time at the time of or after dosing in Treatment 
Period 5 until the Follow-up Visit. 
 
Adverse events with missing start dates/times will be handled as follows: 
x 
If the start date is completely missing but the end date is known and shows that the AE 
ended on or after the first dose date, then the start date will be imputed as the first day of 
dosing; if the end date is known and shows that the AE ended before the first dose date, 
then the screening date will be used for the start date.  If the end date is non-informative 
(i.e., is missing or does not contain enough information), the start date will be imputed as 
the first date of dosing; 
x 
If only the start day is missing the day will be imputed as the first day on which a dose 
was given in that month unless the end date is known and shows that the AE ended before 
a dose was given in that month; in which case the date will be imputed as 01.  If the end 
date is non-informative (i.e., is missing or does not contain enough information), the start 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
70 of 94 
date will be imputed as the first date of dosing in the known month.  If the month is not a 
dosing month the date will be imputed as 01; 
x 
If the start day and month are missing the date will be imputed as the first day of dosing 
in the known year unless the end date is known and shows that the AE ended before a 
dose was given in that year; in which case the start day and month will be imputed as 
01Jan or with the date of screening if this is later.  If the end date is non-informative (i.e., 
is missing or does not contain enough information), the start date will be imputed as the 
first date of dosing in the known year.  If the year is not a year of dosing then the date will 
be imputed as 01Jan or with the date of screening if this is later. 
x 
Missing times will be imputed as 00:00 h or with the time of dosing for events starting on 
a dosing day. 
Adverse events will be summarized by treatment (where treatments will be pooled across 
treatment periods) and overall for all subjects, including tabulations by causality and severity 
(mild, moderate and severe).  All tabulations will be presented by SOC and Preferred Term.  
Furthermore, separate listings of SAEs, AEs that led to discontinuation of the IMP, AEs that 
led to withdraw from the study and AEs that led to death will be presented. 
The following information will be included in the listings: verbatim term, SOC, PT and start 
date/time, end date/time, time from last dose, causality, action taken, whether the AE was 
classified as serious and the outcome. 
All tabulations will include the number and percentage of subjects.  In addition, a separate 
tabulation will be presented showing the number of events by treatment and PT. 
Finally, an overview of all AEs will be presented, separately for the number and percentage of 
subjects and the number of events.  This will include categories for any AE, AEs with the 
outcome of death, SAEs and discontinuations of IMP/withdrawals from the study. 
12.10.2. 
Vital Signs 
The results of the vital signs measurements will be listed by subject and time point including 
the date/time of the assessment, changes from baseline and repeat/unscheduled measurements.  
The baseline for vital signs measurements will be the pre-dose assessment on Day 1 in each 
treatment period.  Descriptive statistics will be presented by treatment and time point for both 
observed values and changes from baseline. 
12.10.3. 
Resting 12-lead Electrocardiogram 
12-Lead ECG results will be listed for each subject. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
71 of 94 
12.10.4. 
Physical Examination 
The baseline/screening results of the physical examination will be documented in medical 
history for each subject. 
Any new or aggravated clinically relevant abnormal medical physical examination finding 
compared to the baseline assessment will be reported as an AE. 
The results of the physical examination will be listed by body system for each subject. 
12.10.5. 
Laboratory Assessments 
Haematology and clinical chemistry values will be listed by subject and time point including 
changes from baseline and repeat/unscheduled measurements.  Summary tabulations including 
absolute value and changes from baseline will be presented by treatment and time point for the 
safety analysis set.  The baseline for the measurements will be the Day -1 assessment 
performed prior to dosing in each treatment period.  Shift tables, by treatment, will also be 
presented. 
The listings will include the following information: test name, date of measurement, reference 
range, result and flags for any measurements that are outside the reference range (e.g., 
AstraZeneca, program, or laboratory ranges).  Clinical laboratory data will be reported in 
System International units in the CSR. 
Additional listings will be presented for the following: 
x 
Urinalysis (macroscopic and microscopic, if applicable). 
x 
Pregnancy testing (including FSH). 
x 
The results of viral serology and the drugs of abuse and alcohol screen will not be listed 
in the CSR. 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
72 of 94 
13. 
ADVERSE EVENTS 
13.1. 
Definitions 
13.1.1. 
Definition of Adverse Events 
An AE is the development of an undesirable medical condition or the deterioration of a pre-
existing medical condition following or during exposure to a pharmaceutical product, whether 
or not considered causally related to the product. 
An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., 
tachycardia, enlarged liver) or the abnormal results of an investigation (e.g., laboratory 
findings, ECGs). 
In clinical studies an AE can include an undesirable medical condition occurring at any time 
after the subject has signed informed consent, including run-in or washout periods, even if no 
specific treatment has been administered. 
The term AE is used generally to include any AE whether serious or non-serious. 
13.1.2. 
Definitions of Serious Adverse Event 
An SAE is an AE occurring during any study phase (i.e., run-in, treatment, washout, follow-
up), that fulfils one or more of the following criteria: 
x 
Results in death 
x 
Is immediately life-threatening 
x 
Requires in-patient hospitalization or prolongation of existing hospitalization 
x 
Results in persistent or significant disability or incapacity or substantial disruption of the 
ability to conduct normal life functions 
x 
Is a congenital abnormality or birth defect 
x 
Is an important medical event that may jeopardize the subject or may require medical 
intervention to prevent one of the outcomes listed above. 
For further guidance on the definition of an SAE, see Appendix 16.1 of this CSP. 
13.1.3. 
Other Significant Adverse Events 
During the evaluation of the AE data, an AstraZeneca medically qualified expert will review 
the list of AEs that were not reported as SAEs.  Based on the expert’s judgment, significant 
AEs of particular clinical importance may, after consultation with the Global Safety 
Physician, be considered Other significant adverse events (OAEs) and reported as such in the 
CSR.  A similar review of other data from laboratory tests, vital signs, ECGs and other safety 
assessments will be performed for identification of OAEs. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
73 of 94
Examples of these are marked haematological and other laboratory abnormalities, and certain 
events that lead to intervention (other than those already classified as serious), dose reduction 
or significant additional treatment.
13.2.
Recording of Adverse Events
13.2.1.
Time Period for Collection of Adverse Events
Adverse Events will be collected from the start of randomization throughout the treatment 
periods up to and including the Follow-up Visit.
SAEs will be recorded from the time of informed consent.
13.2.2.
Follow-up of Unresolved Adverse Events
Any AEs that are unresolved at the subject’s last visit in the study are followed up by the PI 
for as long as medically indicated, but without further recording in the 
.
AstraZeneca retains the right to request additional information for any subject with ongoing 
AE(s)/SAE(s) at the end of the study, if judged necessary.
13.2.3.
Variables
The following variables will be collected for each AE:
x
AE diagnosis/description.
x
The date and time when the AE started and stopped.
x
Intensity.
x
Whether the AE is serious or not.
x
Principle Investigator causality rating against the IMP (yes or no).
x
Action taken with regard to IMP.
x
AE caused subject’s withdrawal from study (yes or no).
x
Outcome.
Additional variables will be collected for all SAEs including treatment given for the event.
The following intensity ratings will be used:
9
Mild (awareness of sign or symptom, but easily tolerated)
10
Moderate (discomfort sufficient to cause interference with normal activities)
11
Severe (incapacitating, with inability to perform normal activities)
Severity is a measure of intensity whereas seriousness is defined by the criteria in 
Section 13.1.2.
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
74 of 94
An AE of severe intensity need not necessarily be considered serious.  For example, nausea 
that persists for several hours may be considered severe nausea, but not an SAE.  On the other 
hand, a stroke that results in only a limited degree of disability may be considered a mild 
stroke but would be an SAE.
13.2.4.
Causality Collection
The PI will assess causal relationship between IMP and each adverse event, and answer “yes” 
or “no” to the question “Do you consider that there is a reasonable possibility that the event 
may have been caused by the IMP?”
For SAEs, causal relationship will also be assessed for other medication, any additional drug 
and study procedures.  Note that for SAEs that could be associated with any study procedure 
the causal relationship is implied as “yes”.
A guide to the interpretation of the causality question is found in Appendix 16.1 of this CSP.
13.2.5.
Adverse Events Based on Symptoms and Signs
All AEs spontaneously reported by the subject or reported in response to the open question 
from the study personnel: “Have you had any health problems since you were last asked?” or
revealed by observation will be collected and recorded in the
When collecting AEs the recording of diagnoses is preferred (when possible) to recording a 
list of signs and symptoms.
However, if a diagnosis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.
13.2.6.
Adverse Events Based on Examinations and Tests
The results from protocol-mandated laboratory tests, vital signs, ECGs and other safety 
assessments will be summarized in the CSR.
Deterioration as compared to baseline in protocol-mandated laboratory values, vital signs, 
ECGs and other safety assessments should therefore be reported as AEs if they constitute a 
clinically significant deterioration from baseline.
If deterioration in a laboratory value or vital sign is associated with clinical signs and 
symptoms, the sign or symptom will be reported as an AE and the associated laboratory result 
or vital sign will be considered as additional information.
Wherever possible the reporting PI should use the clinical, rather than the laboratory term 
(e.g., anaemia versus low Hb value).
CCI

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
75 of 94
In the absence of clinical signs or symptoms, clinically relevant deteriorations in 
non-mandated parameters should be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE.
13.2.7.
Hy's Law
Cases where a subject shows elevation in liver biochemistry may require further evaluation 
and occurrences of AST or ALT ≥ 3 x ULN together with total bilirubin ≥ 2 x ULN will need 
to be reported as SAEs.  Please refer to Appendix 16.3 for further instruction on cases of 
increases in liver biochemistry and evaluation of Hy’s Law.
13.3.
Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the IMP, or to the 
study procedure(s). All SAEs will be recorded in the 
If any SAE occurs in the course of the study, then the PI or other site personnel will inform 
appropriate AstraZeneca representatives immediately, or no later than 24 hours of when he 
or she becomes aware of it.
The designated AstraZeneca representative will work with the PI to ensure that all the 
necessary information is provided to the AstraZeneca patient safety data entry site within 
1 calendar day of initial receipt for fatal and life-threatening events and within 5 calendar 
days of initial receipt for all other SAEs.
For fatal or life-threatening AEs where important or relevant information is missing, active 
follow-up will be undertaken immediately.
The PI or other site personnel will inform AstraZeneca representatives of any follow-up
information on a previously reported SAE immediately, or no later than 24 hours of when he 
or she becomes aware of it.
The reference document for definition of expectedness/listedness is the IB [18] for the 
AstraZeneca drug.
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
76 of 94 
14. 
LEGAL AND ADMINISTRATIVE ASPECTS 
14.1. 
Archiving of Study Documents 
All source documents generated in connection with the study will be retained in the limited 
access file storage area, respecting the privacy and confidentiality of all records that could 
identify the subjects.  Direct access is allowed only for authorized people for monitoring and 
auditing purposes.  Source documents will be handled, stored and archived according to in 
house procedures. 
The Investigator's Site File will be archived by the contract research organization (CRO) for 
15 years after completion of the study. 
14.2. 
Publication of Study Results 
All of the study information and data collected during the study are confidential and the 
property of AstraZeneca.  After completion of the study, AstraZeneca may prepare a joint 
publication with the Investigator.  The Investigator must undertake not to submit any data 
from this clinical study protocol for publication without prior consent of AstraZeneca at a 
mutually agreed time. 
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements. 
14.3. 
Clinical Study Report 
An integrated CSR will be prepared in accordance with the standards of the ICH guideline for 
structure and content of clinical study reports (ICH E3).  Copies of the CSR will be provided 
to the IEC/IRB and the national Regulatory Authority in accordance with regulatory 
requirements and PAREXEL SOPs.  In the event of premature termination of the study or 
other conditions specified in ICH E3, an abbreviated CSR may be prepared. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
77 of 94 
15. 
REFERENCE LIST 
1 
Hyndman D, Liu S, Miner JN. Urate handling in the human body. Curr Rheumatol Rep 
2016;18(6):34. 
2 
Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann. Intern Med 
2005;143(7):499-516. 
3 
Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. 2011. 
Recommendations for the diagnosis and management of gout and hyperuricemia. 
Postgrad Med 2011;123(6 Suppl 1):3-36. 
4 
Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and 
consequences in the Normative Aging Study. Am J Med 1987;82(3):421-6. 
5 
Yamanaka H, Japanese Society of Gout. Japanese guideline for the management of 
hyperuricemia and gout: second edition. Nucleos Nucleot Nucl 2011;30(12):1018-29. 
6 
Chinese Rheumatology Association. Primary gout diagnosis and treatment guideline. 
Chin J Rheumatol 2011;15(6):410-3. 
7 
Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role 
for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 
2006;290(3):F625-31. 
8 
Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: 
a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63(1):102-10. 
9 
Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association 
between serum uric acid and development of type 2 diabetes. Diabetes Care 
2009;32(9):1737-42. 
10 Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in 
chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19(12):1814-
22. 
11 Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid 
and survival in chronic heart failure: validation and application in metabolic, functional, 
and hemodynamic staging. Circulation 2003;107(15):1991-7. 
12 Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an 
independent predictor of all-cause mortality in patients at high risk of cardiovascular 
disease: a preventive cardiology information system (PreCIS) database cohort study. 
Arthritis Rheum 2008;58(2):623-30. 
13 Kim SY, De Vera MA, Choi HK. Gout and mortality. Clin Exp Rheumatol 
2008;26(5)(suppl 51):S115-S119. 
14 Jankowska EA, Ponikowska B, Majda J, Zymlinski R, Trzaska M, Reczuch K, et al. 
Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart 
failure. Int J Cardiol 2007;115(2):151-5. 
15 Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based 
recommendations for the management of gout Ann Rheum Dis. 2017;76:29-42 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
78 of 94 
16 Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR 
evidence-based recommendations for gout, Part II: management: report of a task force of 
the EULAR Standing Committee for International Clinical Studies Including 
Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24. 
17 Jordan KM, Cameron JS, Snaith M, Zhang, W, Doherty M, Secki J, et al. British Society 
for Rheumatology and British Health Professionals in Rheumatology guideline for the 
management of gout. Rheumatology (Oxford) 2007;46(8):1372-4. 
18 Verinurad Investigator’s Brochure, Edition 2, dated 26 October 2018. 
19 FDA Guidance for Industry ‘Food-Effect Bioavailability and Fed Bioequivalence 
Studies’.  December 2002. 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida
nces/UCM126833.pdf 
20 FDA Guidance for Industry ‘Drug-induced liver injury: Premarketing clinical evaluation’.  
July 2009.  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida
nces/UCM174090.pdf 
 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
79 of 94 
16. 
APPENDICES 
16.1. 
Additional Safety Information 
Further Guidance on the Definition of a Serious Adverse Event 
Life-threatening 
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death.  ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (e.g., hepatitis that resolved without hepatic failure). 
Hospitalization 
Outpatient treatment in an emergency room is not in itself an SAE, although the reasons for it 
may be (e.g., bronchospasm, laryngeal oedema).  Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study. 
Important Medical Event or Medical Intervention 
Medical and scientific judgment should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life-threatening or result in 
death, hospitalization, disability or incapacity but may jeopardize the subject or may require 
medical intervention to prevent 1 or more outcomes listed in the definition of serious.  These 
should usually be considered as serious. 
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgment must be used. 
Examples of such events are: 
x 
Angioedema not severe enough to require intubation but requiring intravenous 
hydrocortisone treatment. 
x 
Hepatotoxicity caused by paracetamol/acetaminophen overdose requiring treatment with 
N-acetyl cysteine. 
x 
Intensive treatment in an emergency room or at home for allergic bronchospasm. 
x 
Blood dyscrasias (e.g., neutropenia or anaemia requiring blood transfusion) or 
convulsions that do not result in hospitalization. 
x 
Development of drug dependency or drug abuse. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
80 of 94 
A Guide to Interpreting the Causality Question 
The following factors should be considered when deciding if there is a “reasonable 
possibility” that an AE may have been caused by the IMP. 
x 
Time Course / Exposure to suspect drug: 
Has the subject actually received the suspect drug?  Did the AE occur in a reasonable 
temporal relationship to the administration of the suspect drug? 
x 
Consistency with known drug profile: 
Was the AE consistent with the previous knowledge of the suspect drug (pharmacology and 
toxicology) or drugs of the same pharmacological class?  OR, could the AE be anticipated 
from its pharmacological properties? 
x 
Dechallenge experience: 
Did the AE resolve or improve on stopping or reducing the dose of the suspect drug? 
x 
No alternative cause: 
The AE cannot be reasonably explained by other etiology such as the underlying disease, 
other drugs, other host or environmental factors. 
x 
Rechallenge experience: 
Did the AE reoccur if the suspected drug was reintroduced after having been stopped? 
Note: AstraZeneca would not normally recommend or support a rechallenge. 
x 
Laboratory tests: 
A specific laboratory investigation (if performed) has confirmed the relationship? 
In difficult cases, other factors could be considered such as: 
x 
Is this a recognized feature of overdose of the drug? 
x 
Is there a known mechanism? 
 
Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a 
‘reasonable possibility’ of a causal relationship for the individual case.  The expression 
‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relationship. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
81 of 94 
The causality assessment is performed based on the available data including enough 
information to make an informed judgment.  With limited or insufficient information in the 
case, it is likely that the event(s) will be assessed as ‘not related’. 
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
82 of 94 
16.2. 
International Airline Transportation Association 6.2 Guidance 
Document 
Labelling and Shipment of Biohazard Samples 
International Airline Transportation Association (IATA) classifies bio hazardous agents into 
3 categories (http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.ht
m).  For transport purposes the classification of infectious substances according to risk groups 
was removed from the Dangerous Goods Regulations in the 46th edition (2005).  Infectious 
substances are now classified either as Category A, Category B or Exempt.  There is no direct 
relationship between Risk Groups and Categories A and B. 
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals.  Category A pathogens are for example, Ebola and 
Lassa Fever viruses.  Category A pathogens: 
Are to be packed and shipped in accordance with IATA Instruction 602. 
Category B Infectious Substances are infectious substances that do not meet the criteria for 
inclusion in Category A.  Category B pathogens are for example, hepatitis A, B, C, D and E 
viruses, and human immunodeficiency virus (HIV) types 1 and 2.  They are assigned the 
following UN number and proper shipping name: 
x 
UN 3373 – Biological Substance, Category B 
x 
Are to be packed in accordance with UN3373 and IATA Instruction 650. 
 
Exempt refers to all other materials with minimal risk of containing pathogens. 
x 
Clinical trial samples will fall into Category B or Exempt under IATA regulations. 
x 
Clinical trial samples will routinely be packed and transported at ambient temperature in 
IATA 650 compliant packaging. 
 
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.htm) 
x 
Biological samples transported in dry ice require additional dangerous goods specification 
for the dry ice content. 
x 
International Airline Transportation Association compliant courier and packaging 
materials should be used for packing and transportation.  Packing should be done by an 
IATA certified person, as applicable. 
x 
Samples routinely transported by road or rail are subject to local regulations which 
require that they are also packed and transported in a safe and appropriate way to contain 
any risk of infection or contamination by using approved couriers and packaging / 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
83 of 94 
containment materials at all times.  The IATA 650 biological sample containment 
standards are encouraged wherever possible when road or rail transport is used. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
84 of 94 
16.3. 
Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law 
16.3.1. 
Introduction 
This Appendix describes the process to be followed in order to identify and appropriately 
report Potential Hy’s Law (PHL) cases and Hy’s Law (HL) cases.  It is not intended to be a 
comprehensive guide to the management of elevated liver biochemistries.  
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry. The Investigator is responsible for determining whether a subject meets 
potential PHL criteria at any point during the study.  
All sources of laboratory data are appropriate for the determination of PHL and HL events; 
this includes samples taken at scheduled study visits and other visits including central and all 
local laboratory evaluations even if collected outside of the study visits; for example, PHL 
criteria could be met by an elevated ALT from a central laboratory and/or elevated total 
bilirubin (TBL) from a local laboratory.  
The Investigator will also review Adverse Event data (for example, for AEs that may indicate 
elevations in liver biochemistry) for possible PHL events. 
The Investigator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether HL criteria are met.  
Hy’s Law criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry other than Drug-induced Liver Injury (DILI) caused by the IMP. 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with 
standard safety reporting processes. 
16.3.2. 
Definitions 
Potential Hy’s Law 
x 
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 x ULN 
together with total bilirubin (TBL) ≥ 2 x ULN at any point during the study following 
the start of study medication irrespective of an increase in alkaline phosphatase (ALP). 
Hy’s Law 
x 
Aspartate aminotransferase or ALT ≥ 3 x ULN together with TBL ≥ 2 x ULN, where no 
other reason, other than the IMP, can be found to explain the combination of increases, 
e.g., elevated ALP indicating cholestasis, viral hepatitis, another drug. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
85 of 94 
x 
For PHL and HL the elevation in transaminases must precede or be coincident with (i.e., 
on the same day) the elevation in TBL, but there is no specified timeframe within which 
the elevations in transaminases and TBL must occur. 
16.3.3. 
Identification of Potential Hy’s Law Cases 
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any subject/patient who meets any of the following identification criteria in 
isolation or in combination: 
x 
Alanine aminotransferase ≥ 3 x ULN 
x 
Aspartate aminotransferase ≥ 3 x ULN 
x 
Total bilirubin ≥ 2 x ULN 
If Central Laboratories are Being Used: 
When a subject meets any of the PHL identification criteria, in isolation or in combination, the 
central laboratory will immediately send an alert to the Investigator (also sent to AstraZeneca 
representative). 
The Investigator will also remain vigilant for any local laboratory reports where the PHL 
identification criteria are met, where this is the case the Investigator will:  
x 
Notify the AstraZeneca representative  
x 
Request a repeat of the test (new blood draw) by the central laboratory without delay.  
x 
Complete the appropriate unscheduled laboratory CRF module(s) with the original local 
laboratory test result. 
x 
Determine whether the subject/patient meets PHL criteria (see definition above) by 
reviewing laboratory reports from all previous visits (including both central and local 
laboratory results). 
If Local Laboratories are Being Used: 
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will: 
x 
Notify the AstraZeneca representative 
x 
Determine whether the subject meets PHL criteria (see definition above) by reviewing 
laboratory reports from all previous visits 
x 
Promptly enter the laboratory data into the laboratory CRF 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
86 of 94 
16.3.4. 
Follow-Up  
16.3.4.1. 
Potential Hy’s Law Criteria not Met  
If the subject does not meet PHL criteria the Investigator will: 
x 
Inform the AstraZeneca representative that the subject has not met PHL criteria. 
x 
Perform follow-up on subsequent laboratory results according to the guidance provided in 
the Clinical Study Protocol. 
16.3.4.2. 
Potential Hy’s Law Criteria met  
If the subject does meet PHL criteria the Investigator will:  
x 
Notify the AstraZeneca representative who will then inform the central Study Team. 
x 
Within 1 day of PHL criteria being met, the Investigator will report the case as an SAE of 
Potential Hy’s Law; serious criteria ‘Important medical event’ and causality assessment 
‘yes/related’ according to CSP process for SAE reporting. 
x 
For subjects that met PHL criteria prior to starting IMP, the Investigator is not required to 
submit a PHL SAE unless there is a significant change# in the subject’s condition. 
x 
The Study Physician contacts the Investigator, to provide guidance, discuss and agree on 
an approach for the study subjects’ follow-up (including any further laboratory testing) 
and the continuous review of data. 
x 
Subsequent to this contact the Investigator will: 
 
Monitor the subject until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes follow-up SAE Form as required. 
 
Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician. When central laboratories are used, this includes 
deciding which the tests available in the HL lab kit should be used. 
 
Complete the 3 Liver CRF Modules as information becomes available. 
16.3.5. 
Review and Assessment of Potential Hy’s Law Cases 
The instructions in this Section should be followed for all cases where PHL criteria are met. 
As soon as possible after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the 
IMP, to ensure timely analysis and reporting to health authorities within 15 calendar days 
from date PHL criteria was met.  The AstraZeneca Global Clinical Lead or equivalent and 
Global Safety Physician will also be involved in this review together with other subject matter 
experts as appropriate. 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
87 of 94 
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below. 
Where there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for an SAE: 
x 
If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF. 
x 
If the alternative explanation is an AE/SAE: update the previously submitted PHL SAE 
and AE CRFs accordingly with the new information (reassessing event term; causality 
and seriousness criteria) following the AZ standard processes. 
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP: 
x 
Send updated SAE (report term ‘Hy’s Law’) according to AstraZeneca standard 
processes. 
 
The ‘Medically Important’ serious criterion should be used if no other serious criteria 
apply. 
 
As there is no alternative explanation for the HL case, a causality assessment of 
‘related’ should be assigned. 
If, there is an unavoidable delay, of over 15 calendar days in obtaining the information 
necessary to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternative explanation until such time as an informed decision can be made: 
x 
Provides any further update to the previously submitted SAE of PHL, (report term now 
‘Hy’s Law case’) ensuring causality assessment is related to IMP and seriousness criteria 
is medically important, according to CSP process for SAE reporting. 
x 
Continue follow-up and review according to the agreed plan. Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternative explanation for the liver biochemistry 
elevations is determined. 
16.3.6. 
Laboratory Tests  
The list below represents the standard, comprehensive list of follow-up tests which are 
recommended but not mandatory when using a central laboratory. For studies using a local 
laboratory, the list may be modified based on clinical judgment.  If required, additional 

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
88 of 94 
assistance on which tests could be used to evaluate other potential causes of liver dysfunction 
consult with the Hepatic Safety Knowledge Group. Any test results need to be recorded. 
Hy’s Law lab kit for central laboratories (18 December 2018) 
Additional standard chemistry and coagulation tests 
GGT 
LDH 
Prothrombin time 
INR 
Viral hepatitis 
IgM anti-HAV 
IgM and IgG anti-HBc 
HBsAg 
HBV DNA 
anti-HCV 
HCV RNA* 
IgM anti-HEV 
HEV RNA 
Other viral infections 
IgM & IgG anti-CMV 
IgM & IgG anti-HSV 
IgM & IgG anti-EBV 
Alcoholic hepatitis 
Carbohydrate deficient transferrin (CD-transferrin)** 
Autoimmune hepatitis 
Antinuclear antibody (ANA) 
Anti-Liver/Kidney Microsomal Ab (Anti-LKM) 
Anti-Smooth Muscle Ab (ASMA) 
Metabolic diseases 
alpha-1-antitrypsin 
Ceruloplasmin 
Iron 
Ferritin 
Transferrin 
Transferrin saturation 
* HCV RNA is only tested when IgG anti-HCV is positive or inconclusive  
** Carbohydrate deficient transferrin (CD-transferrin) is not available in China. Study teams should amend this 
list accordingly. 
 
16.3.7. 
References 
Aithal et al 2011, Clinical Pharmacology and Therapeutics 89(6):806-815. 
FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing 
clinical evaluation’. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
89 of 94
16.4.
Actions Required in Cases of a Renal-related or Urolithiasis 
Treatment-emergent Adverse Event or a Serum Creatinine 
Elevation
During the course of the study, the Investigator will remain vigilant for symptoms or signs of 
renal-related events, kidney stone events or changes in renal function.
16.4.1.
Signs and Symptoms Suggestive of Urolithiasis
After initiation of study medication, if a subject experiences signs or symptoms suggestive of 
nephrolithiasis (e.g., flank pain or haematuria), he/she should be evaluated by a physician and 
serum creatinine, blood urea nitrogen (BUN), and urinalysis should be measured via central 
laboratory testing (preferred) and/or local laboratory testing, as appropriate, to determine renal 
function.  Imaging (intravenous urogram, renal ultrasound, or magnetic resonance imaging) is 
recommended to confirm or exclude any urinary tract calculus.  Abnormal results should be 
treated as medically appropriate by the treating physician.  All symptoms, testing, and results 
will be documented in source documents and 
If a subject develops a urinary tract calculus (as confirmed and documented by imaging or 
passage of a stone) at any time during the study, the subject will discontinue randomised study 
medication and be encouraged to remain in the study for continued safety assessments. If the 
urinary tract calculus is passed, it should be collected and submitted to pathology for analysis 
of chemical composition.
16.4.2.
Deterioration of Renal Function
The Investigator should assess subjects exhibiting elevated serum creatinine carefully to 
determine the most likely cause for the deterioration of renal function. Following a thorough 
assessment, the subject should be managed according to local medical practice.  Potentially-
treatable causes such as volume depletion, hypotension etc., should be corrected before 
following the recommendations given below.
Serum Creatinine Increase to ≥ 1.5-fold from Baseline
x
Assess the subject to identify and manage any potential contributing factor.  Correct any 
dehydration and ensure the subject is well hydrated prior any future evaluation.
x
Contact the Sponsor’s lead physician for advice and to discuss discontinuation of study 
medication.
x
Assess creatinine daily if the elevation is detected while the subject is admitted to the 
Clinical Unit, and otherwise weekly.
x
Subsequent management will depend on the repeat measurement(s):
If serum creatinine < 1.5-fold of baseline value for 2 successive measurements, the subject 
may restart/continue with study treatment on the original study visit schedule.
CCI

Clinical Study Protocol 
Revised according to Protocol Amendment No. 1 
AstraZeneca 
Verinurad (RDEA3170) - D5495C00005 
24 June 2019 
CONFIDENTIAL AND PROPRIETARY 
90 of 94 
If repeat serum creatinine is ≥ 1.5-fold of baseline, the subject should be evaluated every week 
until normalization.  The randomised treatment should be permanently discontinued. 

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
91 of 94
17.
SIGNATURES
17.1.
Declaration of Sponsor or Responsible Medical Expert (Physician)
Protocol Title: A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess 
the Relative Bioavailability of 3 Different Extended-release Formulations of Verinurad in 
Healthy Subjects
This clinical study protocol was subjected to critical review.  The information it contains is 
consistent with current knowledge of the risks and benefits of the IMP, as well as with the 
moral, ethical and scientific principles governing clinical research as set out in the Declaration 
of Helsinki (Version 1996) and the guidelines on GCP applicable to this clinical study.
Sponsor Signatory/Responsible Medical Expert
Signature
Date of signature
AstraZeneca R&D Gothenburg
PPD

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
92 of 94
17.2.
Declaration of Sponsor or Responsible Medical Expert 
(Biostatistician)
Protocol Title: A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess 
the Relative Bioavailability of 3 Different Extended-release Formulations of Verinurad in 
Healthy Subjects
This clinical study protocol was subjected to critical review.  The information it contains is 
consistent with current knowledge of the risks and benefits of the IMP, as well as with the 
moral, ethical and scientific principles governing clinical research as set out in the Declaration 
of Helsinki (Version 1996) and the guidelines on GCP applicable to this clinical study.
Sponsor Signatory/Responsible Medical Expert
Signature
Date of signature
AstraZeneca, Gaithersburg, MD
PPD

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
93 of 94
17.3.
Declaration of the Principal Investigator
Protocol Title: A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess 
the Relative Bioavailability of 3 Different Extended-release Formulations of Verinurad in 
Healthy Subjects
This clinical study protocol was subjected to critical review.  The information it contains is 
consistent with current knowledge of the risks and benefits of the IMP, as well as with the 
moral, ethical and scientific principles governing clinical research as set out in the Declaration 
of Helsinki (Version 1996) and the guidelines on GCP applicable to this clinical study.
Principal Investigator
Signature
Date of signature
PAREXEL Early Phase Clinical Unit Berlin
PPD

Clinical Study Protocol
Revised according to Protocol Amendment No. 1
AstraZeneca
Verinurad (RDEA3170) - D5495C00005
24 June 2019
CONFIDENTIAL AND PROPRIETARY
94 of 94
17.4.
Declaration of the Deputy Principal Investigator
Protocol Title: A Randomised, Single-dose, 5-period, 5-treatment, Crossover Study to Assess 
the Relative Bioavailability of 3 Different Extended-release Formulations of Verinurad in 
Healthy Subjects
This clinical study protocol was subjected to critical review.  The information it contains is 
consistent with current knowledge of the risks and benefits of the IMP, as well as with the 
ethical and scientific principles governing clinical research as set out in the Declaration of 
Helsinki and the guidelines on GCP applicable to this clinical study.
Deputy Principal Investigator
Signature
Date of signature
PAREXEL Early Phase Clinical Unit Berlin
PPD